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Clostridium difficile is a pathogen that causes nosocomial antibiotic-
associated diarrhea and colitis. The indigenous gastrointestinal (GI) microbiota 
plays an important role in protecting the host against infection with C. difficile. 
Administration of antibiotics disrupts the GI microbiota thus allowing for C. difficile 
to colonize and cause disease. The overall goal of this project was to understand 
the relationship between antibiotic administration and the role of specific 
members of the indigenous GI microbiota in mediating colonization resistance 
against C. difficile. Mice were treated with two different antibiotic regimens to 
make them susceptible to experimental C. difficile infection (CDI). Clinical signs 
of disease such as weight loss, diarrhea and hunched posture were monitored 
and at necropsy, tissue was harvested for histopathologic and culture-
independent analysis of the gut community. Results from these experiments 
demonstrate that antibiotic administration is associated with major shifts in the 
microbial GI community structure that predispose mice to CDI. Specifically, 
antibiotic-treated mice challenged with C. difficile strain VPI 10463 either 
developed rapidly lethal CDI or were stably colonized with mild disease. The GI 
microbiota of animals with mild disease was predominated by bacteria from the 
family Lachnospiraceae, resembling the baseline community, while the GI 
community of animals with severe disease was predominated by Escherichia 
                                     xiv 
coli. To test the hypothesis that Lachnospiraceae was less permissive to C. 
difficile colonization than E. coli, both Lachnospiraceae and E. coli members 
were isolated from wild-type mice and tested in germ-free mice. Results from 
these experiments indicate that a single Lachnospiraceae isolate (D4), but not E. 
coli, partially restored colonization resistance against C. difficile and improved 
clinical CDI. Thus, understanding how members of the indigenous GI microbiota, 
specifically Lachnospiraceae, interfere with C. difficile colonization could lead to 
new modalities for prevention and treatment of this important infection. 







1.1 Indigenous gastrointestinal (GI) microbiota 
 For almost a century it has been known that humans are inhabited by a 
highly dense and diverse microbial ecosystem. Only now are we beginning to 
understand the many roles that the indigenous GI microbiota play in human 
health, development and disease processes. Knowing the composition and 
function of this ecosystem is a very important step toward understanding the 
many roles of the indigenous GI microbiota. 
 The microbiota (microbiome) refers to the total community of 
microorganisms that reside on and within the host. It is estimated that bacterial 
cells out number human cells by a factor of ten due largely to the extremely high 
density of bacterial cells found in the human GI tract (typically 1011–1012 
microbes/ml of luminal content) (147). Although Bacteria predominate, Archaea 
and Eukarya are also represented. Acid, bile and pancreatic secretions hinder 
colonization of the stomach and proximal small intestine by most bacteria. 
However, bacterial density increases in the distal small intestine and more so in 
the large intestine (114).  
 The microbial ecosystem in the human GI tract serves many important 
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functions. It provides protection against pathogens, assists with nutrient 
processing, stimulates angiogenesis and also regulates host fat storage (96, 97, 
151). In addition, many diseases in humans have suspected links to the GI 
microbiota, including stomach cancer (120), mucosa-associated lymphoid tissue 
lymphoma (94), inflammatory bowel disease (116, 146), and necrotizing 
enterocolitis (50). The intestinal microbiome has metabolic activity that is both 
adaptable and renewable (21). Through the production of short-chain fatty acids, 
resident bacteria positively influence intestinal epithelial cell differentiation and 
proliferation, and mediate other metabolic effects (147). Together, this complex 
metabolic activity recovers valuable energy and absorbable substrates for the 
host, and provides energy and nutrients for bacterial growth and proliferation. 
 
1.2 Molecular methods used to analyze microbial communities 
Previously, much of our knowledge on the microbial ecology of the GI tract 
was described through microbiological culturing techniques. Though it is still a 
useful tool, it is becoming increasing clear that there are serious limitations in the 
application of such techniques to analyze complex microbial communities. Many 
of the bacteria residing in the GI tract are fastidious and require specific growth 
conditions and as a result may be difficult to grow or culture (158). It is estimated 
that over 50% of the species present in the indigenous gut microbiota have not 
been previously cultured (184). Recently, the use of the highly conserved 
phylogenetically informative gene that encodes the 16S rRNA present in all 
bacteria has enabled the development of molecular techniques to characterize 
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the whole microbial community present at a specific time in the GI tract (Figure 
1.1) (93). The key advantage of using the 16S rRNA gene is the presence of 
highly conserved and variable regions, for example, primers can be designed 
based on the conserved regions while the variable regions can be used to 
distinguish different types of bacteria (Figure 1.1) (7). Molecular techniques have 
allowed us to characterize microbial community structure and composition, 
diversity, monitor microbial community dynamics as well as track specific strains 
of bacteria.  
 
 
Figure 1.1 Variable regions of the 16S rRNA gene.The plot represents variable 
(V) and conserved regions of the 16S rRNA gene. The y-axis is the mean 
frequency within a window of 50 bases, moving one base at a time along the 
gene. Conserved regions on the graph are represented by the peaks. The 
locations of the hypervariable regions are labeled with gray bars on the x- axis 
defining these regions as V1 to V9 (From reference (7)). 
 
 Application of modern molecular techniques to study the gut microbial 
community is dependent upon the development of rapid and reliable techniques 
for identifying both culturable and non-culturable species. Characterization of 
microbial community structure and composition can be done using polymerase 
chain reaction (PCR) based techniques that target the 16S rRNA gene such as 
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16S rRNA gene clone libraries, pyrosequencing techniques, denaturing gradient 
gel electrophoresis (DGGE), terminal-restriction fragment length polymorphism 
analysis (T-RFLP) and quantitative PCR. Other common molecular techniques 
require the use of oligonucleotide probes specific for bacterial groups or species. 
These include dot blot hybridization, fluorescent in situ hybridization (FISH) and 
DNA microarray (phylochip) technology. Many of these techniques are 
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No Moderate (I) Have the organism (I) Many GI bacteria are 
difficult to culture 





Yes Very good (I) Large portion of the 16S 
gene is sequenced which 
maximizes the taxonomic 
resolution 
(I) Expensive 




Yes Good (I) Higher through-put 
(II) More sensitive 
(III) Multiple samples can be 
analyzed in a single sequence 
run 
(IV) No cloning bias introduced 
(V) Less susceptible to PCR 
bias 
(I) Shorter sequence 
reads so less robust 
taxonomic resolution 
(II) Error rate per 
nucleotide is high 
DGGE Yes Poor (I) Rapid 
(II) Fingerprints provide a good 
basis to compare communities 
from various treatment groups 
(III) Bands of interest can be 
excised and sequenced 
(I) Short PCR product 
so less taxonomic 
information 
(II) Reproducibility 
between gels is difficult 
TRFLP Yes Poor (I) Fingerprints provide a good 
basis to compare communities  
(II) Multiple restriction 
enzymes can be utilized for 
greater resolution 
(III) Reproducible 
(I) Limited taxonomic 
resolution 
(II) One phylotype can 





Yes Very good (I) Useful for screening 
(II) Fast and easy to use 
(III) Clinical applications 
(I) Detection limited by 
the sequences 
contained on the chip 
(II) Cross-hybridization 
issues 
FISH Yes Good (I) Target specific bacterial 
groups of interest 
(II) Flexible scope: probes can 
target individual bacterial 
species or bacterial groups 
(III) Direct enumeration of 
bacteria-16S copy number is 
not an issue 
(I) Can’t identify new 
bacterial groups 
(II) No a community 
wide survey 
(III) Reference strains 
are required to validate 
results 
(IV) Microscope work 
can be time- consuming 
qPCR Yes Good (I) Target specific bacterial 
groups of interest 
(II) Flexible scope: primers can 
be designed to target groups 
or individual species 
(I) Reference strains 
required  
(II) 16S copy number 
varies  
(III) Can’t identify new 
bacterial groups 
Table 1.1 Summary of techniques used to study the GI microbial community. 
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1.2.1 Characterizing microbial community structure and composition 
A number of methods can be used to generate data that examines 
microbial community structure and composition. The techniques that will be 
discussed are denaturing gradient gel electrophoresis, 16S rRNA gene clone 
libraries and pyrosequencing. 
Denaturing gradient gel electrophoresis 
 Denaturing gradient gel electrophoresis (DGGE) allows the separation of 
amplified DNA fragments of similar size based on the extent of sequence 
divergence between different PCR products (111). A single PCR reaction is 
carried out on whole community DNA and partial 16S rDNA sequences. 
Sequences are then amplified from the different bacterial species present. DNA 
fragments of different sequences have varying melting temperatures. Fragments 
of the same size may be separated on gels that melt double-stranded DNA 
during electrophoresis, using a temperature or chemical denaturant gradient. 
DGGE has the potential to determine the identity of bacterial species present in 
complex microbial consortia without the need for prior sequence information. 
Thus, it provides a powerful tool in initial characterization of both culturable and 
non-culturable microbial communities in a specified system. 
16S rRNA gene clone libraries 
This method involves the use of classical DNA Sanger sequencing. The 
16S rRNA encoding gene from bacterial species found in an experimental 
sample of interest is first amplified by PCR using broad range primers (Figure 
1.2). The amplified 16S rRNA sample is purified and cloned into a vector then 
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transformed into competent cells. These clones are further screened with vector 
specific primers to ensure correct band lengths of the 16S rRNA which are then 
sequenced. Usually a clone library will consist of only 96 clones, which is a small 
number in comparison to the number of sequence reads obtained by newer 
methods such as pyrosequencing. However one advantage is that the 
sequenced 16S rRNA read lengths are long ranging from approximately 500 
base pairs to full length which can be used to identify more accurately the 
organism from which the 16S rRNA gene was derived. Some bias does exist 
when constructing 16S rRNA clone libraries by PCR. These include differences 
in the specificity of polymerases, inhibition of the reaction by interfering 
substances, differential PCR amplification and PCR artifacts (e.g. chimeric 
structures and formation of deletion mutants) (173).   
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Figure 1.2 Schematic overview of 16S rRNA clone library construction. 
Total DNA is extracted from intestinal tissue and 16S rRNA is amplified. 16S 
amplicons are then ligated into a vector then transformed into competent E. coli 
cells. These clones are screened to ensure they contain only a single 16S rRNA 
gene, cultured, DNA extracted and then further amplified prior to sequencing.  
 
Pyrosequencing 
 Pyrosequencing is a new method that was developed as an alternative to 
classical DNA Sanger sequencing. It is highly quantitative, fast and inexpensive 
and has many applications in DNA sequencing, genotyping, single nucleotide 
polymorphism analysis, allele quantification and whole-genome sequencing. 
Depending on the platform used, read lengths can be variable (113). Analysis of 
the 16S rRNA gene by the pyrosequencing technique involves four main stages: 
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first, target DNA is amplified using PCR; second, double-stranded DNA is 
converted to single-stranded DNA templates; third, oligonucleotide primers are 
hybridized to a complementary sequence of interest and, finally, the 
pyrosequencing reaction itself where a reaction mixture of enzymes and 
substrates catalyzes the synthesis of complementary nucleotides. 
Pyrosequencing is now increasingly used for bacterial detection, identification 
and typing. Pyrosequencing can also be partially or fully automated, thus 
enabling the high-throughput analysis of samples (113). Pyrosequencing has 
been applied to a wide range of microbial communities and variable (V) regions 
of the 16S rRNA gene, such as V6 in deep-sea vents microbial communities (41); 
V1, V2, V6 and V3 in human (4, 43) and macaque GI tract (108); as well as V9 in 
soil-derived microbial DNA (136).   
 
1.2.2 Analyzing sequence data 
 An important part of microbial community analysis is the classification of 
sequences into a taxonomic framework. Many methods have been used with 
significant differences in classification results depending on the underlying 
algorithms and parameters used. Once sequence data is generated there are 
many ways in which the data can be analyzed. In this thesis 16S rRNA data was 
analyzed using a operational taxonomic unit (OTU; defined by sequence-based 
phylogenetic distance) approach which involves the use of a bioinformatic 
program such as mothur (http://www.mothur.org) (145). OTUs were binned 
according to 97% sequence similarity and then analyzed in two ways. 
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Phylogenetic names were assigned to each OTU by comparing representative 
sequences from each OTU against known 16S rRNA sequences in a database 
such as the Ribosomal Database Project (RDP) (http://rdp.cme.msu.edu/) (29). 
RDP has been widely used for the classification of 16S rRNA-encoding genes. 
This pipeline processes sequences and clusters them based on similarity to 
sequences in the RDP database (29). In addition to RDP, SILVA 
(http://www.arb-silva.de/) and greengenes (http://greengenes.lbl.gov/cgi-
bin/nph-index.cgi) also provide comprehensive 16S rRNA gene databases to 
which 16S rRNA gene data can be aligned (42, 128). The second way in which 
OTU data was analyzed in this thesis was by examining community structure as 
displayed on a dendrogram. The beta diversity measure Morisita-Horn was used 
to calculate the level of community structure dissimilarity between different 
microbial communities (145).  
  
1.2.3 Other techniques used to enumerate microbial communities 
 Oligonucleotide probes specific for groups of bacteria or bacterial species 
may be designed using the phylogenetic information present in 16S rRNA 
sequence databases.  
Dot blot hybridization  
 Dot blot hybridization involves extraction of total 16S rRNA genes from the 
sample, binding of total rRNA to a membrane and hybridizing the bound rRNA 
with labeled probes of varying specificity. Using probes for selected groups of 
bacteria and universal probes designed to hybridize with 16S rRNA from all 
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bacteria, an estimate of the contribution of selected groups of bacteria to the total 
16S rRNA pool may be achieved by comparing the intensity of reporter 
molecules. Bacteria differ in ribosome content depending on their metabolic 
activity and species. The ratio of bound group specific probe to total bound probe 
is an estimate of bacterial numbers present but this may not correlate directly 
with microbial numbers in situ. Dot blot hybridization has been used to study the 
rumen microbiota and to monitor the important human colonic phylogenetic 
groups in the fecal microbiota of infants (44, 150)  
DNA Microarrays 
 This is a powerful tool that is designed for high throughput screening of 
human GI communities. The first DNA microarray contained probes that were 
designed to detect members of the GI microbiota based on the Agilent platform 
(118, 119). These probes targeted up to 359 microbial species and up to 316 
new OTUs during human microbial ecology studies. More recently, Paliy and 
colleagues developed a more sensitive microarray representing approximately 
775 species using the Affymetrix GeneChip platform (117). This chip detected 
and quantified differences in the gut microbiota of healthy individuals and also 
detected bacterial DNA present in minute amounts (0.00025%) of the total 
community DNA (117). However, there are some biases concerning detection 
limits and hybridization that need to be addressed before these microarray chips 
can become commercially available. 
Fluorescent in situ hybridization (FISH) 
 Fluorescent in situ hybridization (FISH) uses oligo-nucleotide probes that 
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target 16S rRNA gene sequences which then allows the enumeration and 
visualization of whole bacterial cells in situ within GI and fecal samples (3, 30, 
190). Genotypic probes that target the predominant components of the gut 
microbiota are usually tagged with fluorescent markers where changes in fecal or 
the intestinal bacterial population may be quantified using fluorescence 
microscopy. FISH is a truly quantitative technique as intact bacterial cells can be 
counted directly without extraction or amplification of nucleotide sequences. The 
major advantage of FISH is that bacterial populations may be enumerated in a 
culture-independent manner in environmental samples. Similarly, the technique 
allows visualization of target bacterial cells in situ.  
Quantitative polymerase chain reaction 
 Quantitative or Real-time PCR (qPCR) is a variation on the polymerase 
chain reaction (PCR) where the quantity of nucleic acid can be measured. This 
method involves the use of probes or primers that can be designed to detect and 
quantify specific bacteria or bacterial communities. During normal PCR, DNA is 
amplified exponentially during a temperature dependent cycle using DNA 
polymerase. Only the end point product is retrieved for measurement. With 
qPCR, measurements are taken continuously during the amplification run 
correspondingly with the plotting of amplification curves. A fluorescent probe is 
used to detect amplification sits on the gene of interest. As the polymerase tracks 
down the DNA strand it causes the quencher to be released from the probe 
resulting in the fluorescence of the reporter dye. Time points can be visualized as 
soon as DNA is detected and is associated with the concentration of the target 
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DNA (98). Data calculation requires the use of a reference gene which allows for 
the normalization of the results and is usually a gene that is present in single 
copy numbers in the sample tissue.  
 
1.3  Colonization Resistance 
 A major function of the human GI microbiota is colonization resistance. 
Colonization resistance refers to the ability of the microbial community to resist 
invasion by exogenous pathogenic organisms (57, 132). Since it is difficult to 
study colonization resistance in humans, one strategy that has been used to 
study colonization resistance is to disrupt the microbial community in animals by 
using antibiotics followed by challenge with a specific pathogen. In a previous 
study, it was shown that when mice were treated with either high doses of 
ciprofloxacin and levofloxacin or low doses of gatifloxacin and moxifloxacin, the 
level of C. difficile colonization in the mouse cecum increased compared to 
saline-treated controls (1) suggesting that the antibiotics altered the resident gut 
microbiota which allowed C. difficile to colonize. In an earlier study, Van der 
Waaij and colleagues demonstrated that after mice were treated with antibiotics 
there was a reduction in the density of cecal microbiota. In turn, this was 
responsible for a loss of colonization resistance to three experimentally 
introduced invaders (Klebsiella pneumoniae, Escherichia coli and Pseudomonas 
aeruginosa). However, colonization resistance returned over time as the 
indigenous microbiota recovered (170).   
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1.3.1 Mechanisms of colonization resistance  
  Some mechanisms that have been proposed to explain pathogen 
colonization suggest that the normal intestinal microbiota provides a natural 
barrier that is capable of preventing the establishment of pathogenic bacteria (89, 
115, 187). Studies have proposed inhibitory mechanisms to explain what 
changes might be occurring in the GI tract. These include changes in redox 
potential and pH (64, 176), production of inhibitory compounds such as short-
chain fatty acids (SCFAs), hydrogen sulphide production, bacteriocins (53, 64, 
104, 137, 153), competition for nutrients (53) and competition for binding sites on 
the epithelium layer of the GI tract (161, 176). The GI microbiota can also 
influence colonization resistance through modulation of host immune responses. 
For instance, lipopolysaccharide (LPS) produced by Gram- negative bacteria is 
recognized by the immune system and in one study of vancomycin resistant 
Enterococcus (VRE), the administration of LPS to mice was shown to up-regulate 
an antimicrobial peptide, RegIIIγ which targets Gram-positive bacteria such as 
VRE and inhibited its colonization in mice (27). The host itself can also play a 
role in preventing pathogen virulence. For example, a study performed by 
Savidge and colleagues demonstrated that C. difficile toxins, which are 
necessary for virulence and disease, were changed chemically by S-nitrosylation 
by the infected host. This process inhibited cleavage of both TcdA and TcdB 
thereby preventing cell entry and attenuated C. difficile virulence (143). 
The mechanisms which enable pathogens such as C. difficile to colonize 
the GI tract of humans are not very clear (137). Studies performed by Freter and 
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colleagues suggested several important factors in the gut that were necessary for 
controlling the bacterial ecosystem, principally- competition for adhesion sites to 
the gut wall and limiting nutrition (52). The notion of competition for adhesion 
sites was developed from a number of studies performed in the past. Itoh and 
colleagues observed that when germ-free mice were colonized with a number of 
anaerobic Clostridia prior to C. difficile challenge, C. difficile was eliminated from 
the GI tract of the animals. However, a similar effect was not observed when 
aerobic bacteria was used (69). Other studies have shown that anaerobic 
Clostridia in mice were able to associate closely with the mucosal layers of the 
cecum and colon (81, 142).  When the ceca of conventional hamsters were 
subjected to scanning electron microscopy, spiral shaped organisms were 
observed at the opening of crypts in the cecum but these organisms were not 
observed in hamsters treated with clindamycin that had CDI (100). In addition, 
Savage and colleagues demonstrated that after the administration of antibiotics 
via oral gavage, the bacterial layers in the mucus and on the epithelial surfaces 
of the murine cecum and colon disappeared (141). A similar effect was also 
observed during dietary and environmental stress (159). These studies provide 
some evidence that occupancy of a specific niche by anaerobic organisms might 
be important for colonization resistance against C. difficile. 
A number of Lactobacilli species have been explored in vitro to examine 
whether they can inhibit C. difficile growth or toxin production. These studies 
demonstrate that only specific strains of Lactobacilli are capable of inhibiting C. 
difficile. It was speculated that the inhibition observed was associated with the 
                                     16 
production of hydrogen peroxide, lactic acid, bacteriocins or the release of a 
bioactive compounds which inhibit cytotoxin production (11, 112). However many 
of these studies were performed using in vitro models which might not be a true 
representation of what occurs in vivo. 
 Because of the complexity of studying the microbiota, in this thesis I will 
examine the roles of individual members of the normal indigenous gut microbiota 
in mediating colonization resistance against C. difficile in germ-free mice.  
 
1.3.2  Short-chain fatty acid (SCFA) production in the GI tract 
 Many researchers believe that SCFAs play a role in colonization resistance 
(35, 52, 137, 153). Bacterial fermentation of complex polysaccharides is an 
important component of the human digestive process (104). Fermentation of 
dietary fiber typically results in SCFAs such as acetic, propionic, butyric, 
hexanoic and valeraic acids being produced as end products. Acetate, 
propioniate and butyrate are normally found in concentrations of 90 to 120 mM 
and are rapidly absorbed in the colon (37, 104).  
 Fermentation is the process by which small amounts of energy is derived 
from the oxidation of organic compounds, such as carbohydrates, and involves 
the use of an endogenous electron acceptor which is also an organic compound 
(36). The types of carbohydrates used are primarily from plant cells such as 
cellulose, pectin, starches, dextran and soluble carbohydrates (18) and the 
principle end products are usually SCFAs (36). Bacteria can undergo different 
types of fermentation and in return produce different end products. During 
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fermentation, pyruvate is metabolized to various compounds. For example, 
homo-lactic fermentation is the production of lactic acid from pyruvate; alcoholic 
fermentation is the conversion of pyruvate into ethanol and carbon dioxide; and 
hetero-lactic fermentation is the production of lactic acid as well as other acids 
and alcohols. 
Fermentation takes place throughout the GI tract of all animals, but the 
intensity of fermentation depends on the number of bacteria present which are 
generally the highest in the large intestine (18). Thus, the large intestine is 
quantitatively the most important site of fermentation in humans. Many bacteria 
prefer to ferment carbohydrates than protein and therefore saccharolytic bacterial 
fermentation occurs predominantly in the proximal colon. On the other hand, if 
the supply of fermentable carbohydrates is depleted, proteolytic fermentation will 
occur in the distal colon (36). The latter is considered less favorable for the host 
because potentially toxic metabolites are formed such as ammonia, sulphur 
containing compounds, indoles and phenols (59). The quantity and proportions of 
volatile fatty acids produced by colonic bacteria are determined by the amount 
and type of substrate fermented. For instance, diet can change the metabolic 
activities of bacteria and as a result diet can influence the quantity and types of 
fermentation end products produced (18). 
1.3.3 Functions of short-chain fatty acids in the GI tract 
Dietary fiber is the major source of energy to support microbial populations 
in the GI tract (10). The chemical properties of dietary fiber as well as its 
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fermentation in the intestine have an important role in keeping the balance 
between communities of resident microbes and pathogens (110). SCFAs are the 
major contributors of energy from fermentation to the host and are rapidly 
consumed by the enterocyte (10, 133). Butyrate in particular is rapidly consumed 
by colonic enterocytes (139). The concentration of SCFA in the intestines may 
reduce the pH. A more acidic pH may inhibit the proliferation of some pathogens 
such as E. coli (110), C. difficile (104) and Salmonella sp. (34).  
In addition, SCFAs have a trophic effect in the intestine, increasing the 
enterocyte turnover rate (134, 160). All of these described effects of SCFAs in 
digestive physiology help in maintaining the integrity of the intestinal mucosa, 
which acts as a barrier to protect against colonization by pathogenic bacteria 
(103). Butyrate also exhibits diverse regulatory functions on cell growth and 
differentiation, ion transport, and immunity in the intestinal epithelium (60, 80, 
165, 171). Gram-negative foodborne pathogens, such as Salmonella 
typhimurium and enterohemorrhagic E. coli, alter virulence gene expression in 
response to butyrate, highlighting an important role for butyrate in host-pathogen 
interactions in the GI tract. SCFAs may also ameliorate diarrhea and prevent 
dehydration by promoting reabsorption of water and sodium in the large intestine 
(135). 
 Many studies theorize that increased concentrations of SCFAs causes a 
reduction in pH which is capable of limiting C. difficile growth and toxin 
production (104). Some studies have looked both in vitro and in vivo at the effect 
of butyrate to inhibit C. difficile growth and toxin production. However, many of 
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these studies are contradictory (137, 153). One study measured the physiological 
levels of various SCFAs in hamster ceca and translated these physiological 
concentrations in vitro to test the ability of each SCFA to inhibit C. difficile growth. 
This study demonstrated that in vitro inhibition of C. difficile by all SCFAs was 
correlated with pH and the concentrations of SCFAs in the cecum (137). They 
also determined that only butyric acid reached a concentration in the hamster 
ceca that was inhibitory to C. difficile growth in vitro (137). On the other hand, 
germ-free mice di-associated with C. butyricum (a butyrate producer) and C. 
difficile did not change the levels of C. difficile colonization even though there 
was a 20-fold increase in the concentration of butyric acid compared to C. difficile 
mono-associated mice (153). Although these studies on SCFAs are 
contradictory, both still conclude that SCFAs may play a role in preventing C. 
difficile colonization but other mechanisms are also involved.  
 
1.4 Effect of antibiotics on the GI microbiota 
Since the development of penicillin, antibiotic therapy has been used for 
the treatment of many infectious diseases. However, antibiotic therapy can affect 
not only the targeted pathogen but also the normal indigenous microbiota of the 
host. The impact on non-targeted microbial populations depends on the particular 
antibiotic used, its mode of action, and degree of resistance in the particular 
community (71). Antibiotics vary in their spectrum of activity and thus can be 
used to selectively target bacterial populations that inhabit mucosal surfaces. 
Many studies have been aimed at characterizing antibiotic-induced changes in 
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the intestinal microbiota and the impact on intestinal colonization by pathogens 
such as vancomycin resistant Enterococcus (VRE) (167), Helicobacter pylori 
(70), and C. difficile (178). Antibiotic treatment can decrease the density and 
dramatically alters the community structure of the intestinal microbiota (132). 
Other studies have also examined the ability of the murine gut microbial 
community to recover following antibiotic treatment. For instance, Antonopoulos 
and colleagues treated mice with different antibiotic regimens. The gut 
community of mice that were treated with a cocktail of amoxicillin, bismuth, and 
metronidazole returned to baseline following a two-week recovery period. On the 
other hand, cefoperazone treatment resulted in prolonged alteration of the gut 
community structure after a six-week recovery period (5).  
 Certain antibiotics are specifically active against anaerobic bacteria that are 
dominant in the human intestinal microbiota. Anaerobes play an important role in 
maintaining gut homeostasis by producing extensive amounts of SCFAs (144). 
Therefore, treatment with antibiotics that select against important groups of 
anaerobic bacteria can have substantial consequences for the resultant 
functional stability of the microbiota. One example is clindamycin, a relatively 
broad-spectrum antibiotic that primarily targets anaerobic bacteria. Clindamycin 
is excreted in bile and concentrations can be high in feces. It has been shown to 
have a large negative impact on the intestinal microbiota which can lead to 
colonization by pathogens such as C. difficile (14, 16).  
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1.5  Clostridium difficile  
 Clostridium difficile is a Gram-positive, spore-forming rod that belongs to the 
family Clostridiaceae and the genus Clostridium. It is a motile bacterium that is 
variably aerotolerant (2, 179). C. difficile was first isolated in 1935 from stool 
samples of newborn children and was named Bacillus difficilis because it was 
difficult to culture (58). Vegetative cells of C. difficile are typically larger than 
other bacterial cells measuring 3 - 16.9 µm in length, 0.5 -1.9 µm in width and 
producing sub-terminal spores (61) that are highly resistant to most standard 
forms of sterilization and disinfection. C. difficile is a heterotrophic organism with 
an optimal growth temperature of 37°C, most strains are motile and possess 
peritrichous flagella. Colonies of C. difficile following 48 hours incubation in 
anaerobic conditions at 37°C are typically large, flat and slightly grey in color. C. 
difficile also has a distinctive odor primarily due to the production of iso-valeric 
acid, iso-caproic acid and p-cresol, which are the products of various metabolic 
pathways within the organism (95). 
 C. difficile  was initially identified as a commensal organism of the digestive 
tract in young infants (58). It was not until 1977 that a clostridial toxin was 
isolated from patients with pseudomembranous colitis (PMC) (88). In 1978 C. 
difficile was identified as the causative agent of antibiotic-associated 
pseudomembranous colitis (PMC) and was acknowledged as a human pathogen 
(17, 55, 89). 
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1.5.1 C. difficile virulence factors 
 Clostridium species produce many protein toxins that contribute to their 
virulence (73). It has been shown that some strains of C. difficile possess flagella 
(the components of flagella FliC (flagellin) and FliD (flagellar cap protein)) (163) 
which are involved in cell adhesion while other strains lacking flagella are unable 
to adhere to cells in vitro (162). Capsules have also been observed in some 
strains of C. difficile which may provide evasion from the host immune system 
(38). The surface layer proteins of C. difficile have been proposed to have 
immunoreactive properties (8) and are also involved in adhesion to host cells 
(25). Other cell surface factors reported to have adhesive properties include 
fibronectin binding proteins (63), Cwp66 (177) and the heat shock protein GroEL 
(62). It has also been reported that some of these proteins also stimulate an 
immune response (122). 
Toxin A (TcdA) and Toxin B (TcdB) 
 C. difficile produces two major protein exotoxins; Toxin A (TcdA) and Toxin 
B (TcdB) that are high molecular weight glucosyltransferases (308kDa and 
270kDa). Some C. difficile strains produce both TcdA and TcdB, while some C. 
difficile strains do not produce any toxin. Non-toxin producing strains of C. difficile 
are not associated with disease (78). C. difficile strains that are TcdA-/B+ have 
been identified. However, to date no TcdA+/B- strains have been identified.
 Toxin A and B are encoded by the genes tcdA and tcdB respectively, which 
reside on the 19.6kb pathogenicity locus (PaLoc) in addition to the genes tcdC, 
tcdD and tcdR (83). The genes tcdC and tcdD are the respective negative and 
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positive regulators of the toxin genes (68). There is also growing evidence which 
suggest that another gene, tcdE, located outside of the PaLoc is responsible for 
holin function and facilitate the release of the toxins from the cell (157).  
 Research into the action of both toxins has been difficult since C. difficile is 
hard to genetically manipulate. Until recently, the virulence of strains that only 
produce TcdA could not be investigated because they are not found naturally in 
nature (102). New methodologies to genetically manipulate C. difficile have 
recently allowed novel studies to be carried out that investigate the independent 
action of both toxins in a hamster model. In contrast to earlier work, these results 
have suggested that TcdB is essential for virulence while genetically altered 
strains that only produce TcdA markedly lose the ability to cause disease (102). 
Such evidence also conflicts with earlier work which suggested that TcdA and 
TcdB work synergistically (84, 101). Thus, some controversy about which toxin is 
more important still remains. 
 Both TcdA and TcdB are produced during the late log and stationary 
phases of C. difficile growth (175) allowing cells to become established within the 
host gut before toxin production begins. Toxins are taken up by host cells 
through receptor-mediated endocytosis (166). The receptors for both toxins 
differ, with the receptor for TcdA better characterized than that for TcdB. The 
receptor for TcdA is the disaccharide Galß1- 4GlcNac found on I, X and Y blood 
antigens that are expressed on several types of cells such as intestinal epithelial 
cells (166). The receptor for TcdB has not yet been identified but its ability to 
infiltrate a variety of cells suggests a common receptor (175). When both the 
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toxin and receptor are internalized, the endosome enclosing them is acidified. 
This allows the toxin to undergo structural transformations upon which the active 
portions of the toxin (catalytic domain) are released into the cytosol (46, 56). Both 
toxins exert their effect on cells by glycosylating the Rho family of proteins (Rho, 
Rac, Cdc 42); proteins which are essential for many processes within the cell 
including regulation of the actin cytoskeleton, disruption of tight junctions and 
parts of the cell cycle (46, 56).  
 Glycosylation of the Rho GTPases leads to inactivation and inhibition of 
their regulatory activity within the cell, most notably leading to de-polymerization 
of the actin cytoskeleton and rounding of the cells and ultimately apoptosis. Cell 
rounding also leads to the disruption of tight junctions due to both the loss in the 
structure of the actin cytoskeleton but also because Rho proteins also regulate 
tight junctions. The loss of tight junctions then leads to increased permeability 
causing the diarrhea that is characteristic of C. difficile infection (CDI) (127).  
 In addition to TcdA and TcdB, some strains of C. difficile also produce a 
binary toxin (CDT) that has been identified as an actin-specific ADP-
ribosyltransferase. This toxin is similar to other clostridial iota toxins which act 
specifically on actin within the cell (125). The role of the binary toxin in CDI is still 
unknown at present but this toxin has been shown to have a cytopathic effect on 
Vero cells (African green monkey kidney epithelial cells) in vitro (123). Not all 
strains of C. difficile produce CDT suggesting that this toxin is not essential to the 
virulence of the organism. The production of binary toxin is most frequently seen 
alongside TcdA and TcdB and is produced primarily by the PCR ribotype 027 
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strains (26). However, to date no studies have identified an association between 
CDT and disease phenotype.  
C. difficile spore production 
 The ability of C. difficile to produce highly resilient endospores enables 
effective transmission and survival within an environment (24). Spores also allow 
the organism to persist within the gut despite antibiotic treatment thereby 
providing a type of resistance. The nosocomial transmission of C. difficile can be 
largely attributed to the ingestion of spores that have been picked up from 
contaminated surfaces or through aerial transmission (168). Spore formation 
allows C. difficile to spread efficiently (91). Sporulation occurs when vegetative 
cells of C. difficile are exposed to conditions that are not favorable such as 
nutritional deprivation (149). In such environments a spore is formed within the 
mother cell. This ensures the preservation of the strain until conditions are such 
that the spore will be stimulated to germinate into its vegetative cell state where it 
can produce toxin and cause disease.  
 Spores of C. difficile germinate in the presence of certain bile salts which 
are found in the small intestine of humans (182). Therefore, it is likely that this is 
the site where germination occurs. There are several bile salts that induce the 
germination of C. difficile spores, however taurocholate is the most effective and 
well documented; glycine and thioglycolate also act as co-germinants (149, 180).  
 
1.6 Clostridium difficile infection (CDI) 
 Signs of CDI can range in severity from mild to moderate diarrhea or colitis, 
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sometimes accompanied by abdominal pain, fever, nausea, lethargy and 
dehydration to severe pseudomembranous colitis, sepsis, toxic megacolon and 
even death. In uncomplicated cases, CDI can often be resolved by 
discontinuation of the offending antibiotic, and rehydration therapy if required. In 
more serious cases of CDI, antibiotics such as metronidazole or vancomycin may 
be required to eliminate C. difficile from the gut. 
 The asymptomatic carriage of C. difficile in adults is reported to be due to 
previous infection (131), prior hospitalization (12) and also possible carriage of 
non-toxin producing isolates (40). The high rates of asymptomatic carriage 
amongst neonates are believed to be due to the immaturity of gut receptors to 
which C. difficile toxins can bind (183). It is well documented that the infant gut 
microbiota is different from adults (118, 169). Therefore it is thought that the 
maturation of the healthy gut microbiota bolsters colonization resistance in 
infants thereby eradicating C. difficile prior to receptor maturity (45). The 
significant difference in the reported carriage rates of C. difficile between infant 
and adult populations indicates that colonization resistance provided by the 
indigenous GI microbiota are influential in CDI outcome and may be an important 
factor in determining asymptomatic carriage. Asymptomatic carriage can be due 
to non-toxigenic strains or toxin producing strains but any pathogenic effect may 
be inhibited by the presence of an intact, undisturbed gut microbiota. 
 
1.6.1 Clinical manifestations of C. difficile infection 
Antibiotic-associated diarrhea (AAD)  
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 AAD is a common complication of antibiotic use (20). It is described as 
unexplained episodes of diarrhea that begin during or up to two months following 
cessation of antibiotic therapy (47). Infectious AAD results from the disruption of 
the normal indigenous gut microbiota, and overgrowth of opportunistic 
pathogenic bacteria. Overgrowth of C. difficile is the predominant cause of 
infectious AAD. However, a large proportion of AAD cases are not due to 
infection and are often the result of varied physiological responses to antibiotics 
within the gut (66). 
Pseudomembranous colitis 
 Pseudomembranous colitis (PMC) is primarily caused by C. difficile. 
Clindamycin was implicated as the cause of PMC in 1974 (164). PMC only 
occurs in 10% of AAD cases (106) but C. difficile is implicated in over 90% of 
these PMC cases. Symptoms of PMC include profuse watery diarrhea and 
severe abdominal pain, often accompanied by fever, swelling and tenderness of 
the abdomen (78). Endoscopic examination of the colon reveals the presence of 
yellow pseudomembranous plaques. Histopathologically, these lesions consist of 
dead mucosal cells, mucus, fibrin and neutrophils with the extent of plaque 
formation often correlating with the severity disease (78).  
Perforation 
 This condition occurs in approximately 1-3% of all cases of CDI and is 
associated with mortality. Patients experience severe abdominal pain and 
distension, nausea, fever and tachycardia. It is defined as the complete 
penetration of the GI wall resulting in the release of intestinal contents into the 
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abdominal cavity. This may result in peritonitis (infection of the abdominal cavity). 
Surgical intervention is often required to prevent further complications and death 
(78). 
Toxic megacolon 
 Toxic megacolon is a condition whereby the colon rapidly dilates. The 
dilation of the colon also causes abdominal distension and tenderness with fever. 
Toxic megacolon is a rare but life-threatening complication of CDI associated 
with a high risk of perforation, sepsis and shock. Treatment of toxic megacolon is 
usually through surgery by performing either a partial or total colectomy. Steroids 
can also be administered to reduce inflammation and dilation (9). 
 
1.7 C. difficile recurrence and re-infection  
 Recurrent CDI is a complication that occurs in approximately 7-35% of 
patients after the initial resolution of infection (13, 47). It typically occurs 1 to 2 
weeks after completion of antimicrobial therapy for CDI, but may take up to three 
months to develop (74). It is not clear why recurrence of CDI is so high in 
comparison to other infections. However some studies have identified several 
important risk factors for the development of recurrent CDI, including inadequate 
antibody response to toxin A, persistent disruption of colonic microbiota, being 
older than 65 years, prolonged hospital stays, severe illness, use of antibiotics 
other than C. difficile therapy during or after an episode of CDI, and use of 
immunosuppressive medications (109). Recurrence is often associated with 
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treatment failure where C. difficile has not been successfully eradicated from the 
GI tract. Following cessation of antibiotic therapy, the patient again becomes 
symptomatic due to the same strain. It has been suggested that the retention of 
spores within the gut that are unaffected by antibiotic therapy are likely to be a 
contributing factor (78, 105).     
           Another explanation for the high recurrence rates associated with CDI is 
the possibility that the observed recurrence is due to re-infection. Re-infection 
with the same or different strain of C. difficile is likely to occur while a patient is 
still recovering from a previous episode of CDI. Studies that have investigated 
recurrent CDI have reported high levels of re-infection (13, 181). It can take up to 
three months for the GI tract microbiota to become properly re-established 
resulting in the patient becoming vulnerable to infection for a prolonged period of 
time (105).  
 
1.8 Immune response in C. difficile infection 
 An individual’s immune response to C. difficile can influence the extent and 
severity of disease (77). Individuals that are immune-compromised are at an 
increased risk of CDI; however more subtle differences between hosts can also 
influence the symptoms that a person may experience. Studies have 
demonstrated that higher antibody levels towards the toxin can provide protection 
against both symptomatic infection and recurrence of infection in patients who 
have previously suffered from an episode of CDI (6, 79, 86, 87). This has 
provided the basis for using immunoglobulin therapy as a treatment option (140). 
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It has also been shown that an alternative genotype in the IL-8 gene may be 
associated with predisposing patients to CDI (72). 
 
1.9 C. difficile infection treatment options 
Antibiotics 
 Metronidazole and vancomycin are two antibiotics that are commonly used 
for the treatment of patients with CDI. Metronidazole displays bactericidal activity 
towards both protozoa and many anaerobic bacteria. Metronidazole is now the 
preferred treatment in the majority of CDI cases as it is more cost effective and 
selective than vancomycin (85). The selective activity of metronidazole is 
attributed to a unique metabolic pathway found only in protozoal and anaerobic 
cells. When metronidazole diffuses into a cell with a low redox potential, 
ferredoxin donates electrons to the nitro group present on metronidazole. The 
reduction of the nitro group allows the drug to take on its active form generating 
compounds that interfere with nucleic acid synthesis and ultimately leading to cell 
death. Metronidazole is most effective when administered orally and is almost 
completely absorbed. It has also been suggested that metronidazole is equally 
effective when administered intravenously and can even achieve higher 
therapeutic levels (22).  
 Vancomycin is a potent glycopeptide antibiotic used in the treatment of 
severe Gram-positive infections. Vancomycin has a bactericidal effect on cells by 
inhibiting the synthesis of the peptidoglycan cell wall and is administered 
intravenously for the majority of infections. However, this can lead to side effects 
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and problems relating to toxicity. Vancomycin is a large hydrophilic molecule and 
does not transfer across the intestinal wall effectively, thus treatment of CDI 
requires oral administration in order to establish the high therapeutic 
concentrations needed in the GI tract. In recent years the use of vancomycin for 
the treatment of CDI has increased although concerns regarding the acquisition 
of vancomycin resistance by other organisms in the gut still exist (85). 
Vancomycin is commonly used in cases of multiple CDI recurrence, pregnancy, 
allergy and unresponsiveness to metronidazole (126). 
 Recently a new drug, Fidaxomicin was approved by the Federal Food and 
Drug Association (FDA) for the treatment of CDI. It belongs to the macrolide 
class of antibiotics and has narrow spectrum activity against Gram-positive 
Clostridia. It is a RNA polymerase inhibitor with bactericidal activity against C. 
difficile. Clinical trials suggest that this drug causes minimal disruption of the 
indigenous gut microbiota resulting in the maintenance of the normal 
physiological environment of the colon which suggests that the incidence of 
recurrence might be decreased (99). 
Probiotics 
 Probiotics are live microorganisms which have a beneficial effect on the 
intestinal balance of the host when ingested (54). The role of probiotics as both a 
prophylactic and treatment option in CDI has been greatly debated and their 
effectiveness has been highly variable in many studies (92, 107, 188). Common 
probiotics used in humans are Lactic acid bacteria, Bifidobacteria and 
Saccharomyces boulardii. Hickson and colleagues performed a randomized, 
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placebo-controlled study examining the efficacy of preventing AAD and CDI in 
135 hospitalized patients receiving antibiotics. This study demonstrated that 
consumption of a probiotic drink containing Lactobacillus casei, Lactobacillus 
bulgaricus, and Streptococcus thermophilus led to a lower incidence of AAD and 
CDI (65). Other studies that have investigated the effectiveness of probiotics in 
either the prevention or treatment of CDI have failed to provide any strong 
evidence for their use (124). 
Immune therapies 
  The C. difficile vaccine (ACAM C.diff) is a toxoid vaccine currently in Phase 
II clinical trials in the UK (85). If the vaccine proves to be effective it has been 
proposed for administration to high-risk patient groups. In current clinical trials, 
the vaccine is being administered to individuals experiencing their first episode of 
CDI with the hope that the vaccine will prevent recurrence. The vaccine contains 
toxoid A and toxoid B which simulate an immune response to both toxins through 
the production of serum IgG antitoxin A and serum IgG antitoxin B antibodies 
(82). 
Fecal therapy 
 The aim of fecal transplant therapy is to re-colonize the GI tract with a 
population of indigenous bacteria similar to those present in the patient prior to 
infection. Fecal transplant therapy is not widely available or an approved therapy. 
In a review by Van Nood and colleagues, it was reported to be extremely 
effective in both the treatment and the prevention of recurrences of CDI (172). 
These studies provide evidence for the important role of the gut microbiota in 
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colonization resistance against C. difficile.  
1.10 Animal models of C. difficile infection 
 Several animal models such as hamsters, hares, guinea pigs, germ-free 
mice and piglets, rats and conventional mice have been used to study CDI. In the 
past, the most commonly used model to study C. difficile pathogenesis was the 
Syrian golden hamster (15, 49, 148). Although the results of in vivo CDI studies 
are dependent on the particular strain of C. difficile that is used in an experiment, 
many studies tend to highlight common findings (156). First, the mortality of 
untreated C. difficile diarrhea in hamsters is close to 100%. Secondly, all 
antimicrobial agents that have shown treatment efficacy in vivo can also be used 
to precipitate the disease in hamsters. Lastly, while both vancomycin and 
metronidazole protect infected hamsters during therapy, once therapy is 
discontinued the organism and cytotoxin becomes detectable in the stool and the 
animals succumb within 2 to 9 days (15, 49). When strict animal housing or 
handling methods have been employed in these experiments the mortality rates 
drop. This suggests that these animals are still susceptible following vancomycin 
treatment and that conventionally housed hamsters re-acquire the organism in 
the form of spores present in their environment (49).  
 C. difficile infection in the hamster can also represent a model of human 
infant asymptomatic infection. Infant hamsters are susceptible to C. difficile 
colonization at an early age but this susceptibility is lost with the establishment of 
the normal indigenous microbiota (138). After two weeks of age C. difficile 
infection is completely dependent on exposure to antimicrobial agents (187). The 
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primary site of infection in antibiotic-treated hamsters is the cecum, an organ in 
rodents that is proportionately much larger than in humans, but which serves 
functions similar to that of the human colon (138).  
 The hamster model has been used for three decades to study CDI therapy 
and mechanisms of disease. However, the hamster model has some limitations. 
For instance, the model represents a lethal course of disease (48) when 
toxigenic C. difficile strains are used. This does not represent the usual course 
and spectrum of CDI observed in adults which is usually a gradual onset with 
varying levels of severity. There is also a lack of both molecular tools and 
immunologic reagents for hamsters when compared to mice and other rodents 
(28).  
 Apart from the hamster model, guinea pigs have been used to study various 
aspects of C. difficile pathogenesis. Xia and colleagues used guinea pigs to 
examine whether the intestinal actions of C. difficile toxin A have a neurally 
mediated component. They found that toxin A affected the electrical behavior of 
the neuronal cell bodies (189). Although these researchers described the guinea 
pig as a model, the method used involved the removal of segments of the guinea 
pig small intestine which were then mounted into recording chambers to measure 
the effects of C. difficile toxin A.  
 In neonatal pigs, C. difficile has become a common cause of enteritis (19, 
39). Steele and colleagues demonstrated that germ-free piglets were consistently 
colonized with C. difficile following oral gavage (152). Piglets challenged with a 
non-toxigenic strain of C. difficile did not develop signs of CDI. These 
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researchers also demonstrated that depending on the C. difficile challenge dose 
and the age of the piglet, it resulted in the induction of either acute and severe 
CDI or mild chronic disease. Infected piglets seem to mimic many of the key 
features of CDI in humans and as a result could be used investigate C. difficile 
strain severity (152). 
 
1.11 Murine CDI models 
 Previously, conventional rodents such as mice or rats were not readily 
susceptible to CDI (89, 115, 137), but studies using germ-free mice and rats 
have shown that these animals can be colonized by the organism and develop 
intestinal pathology (115, 154, 186). Germ-free rodents offer a well-defined 
model to study the pathogenicity of C. difficile because it is possible to study the 
interaction of C. difficile and its toxins with the host without any influence of other 
bacteria. In this model, animals are infected by toxinogenic C. difficile strains and 
develop lethal cecitis (32, 115, 186). Germ-free animals also develop 
pseudomembranes in the colon as observed with CDI in humans. Depending on 
the strain of C. difficile used in an experiment there may be varying degrees of 
severity. Some studies have shown that germ-free mice may remain colonized 
with a low toxin producing strain C. difficile for as long as 30 days with chronic 
inflammation (115, 185) while others have demonstrated that germ-free mice 
succumb to the infection when high toxin producing strains of C. difficile are used 
(32, 33).  
 Other studies have tried to conventionalize germ-free mice by colonizing 
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their GI tract with microbiota from humans, hamsters or wild-type mice to study 
factors that prevent C. difficile colonization (32, 153, 185, 186). For instance 
when the hamster microbiota is introduced into germ-free mice, their usually 
large cecum is reduced to conventional size, C. difficile colonization is 
suppressed and the hypocellularity that is normally characteristic of the small 
bowel of germ-free mice is corrected (186).  
 Germ-free mice also provide a model in which to study the role of the 
indigenous microbiota in contributing to colonization resistance against C. 
difficile. In this thesis I have utilized this model to examine the ability of specific 
indigenous gut bacteria to limit C. difficile colonization and disease severity. 
However there are limitations with this model. Germ-free animal models are far 
more expensive and less amenable to experimental use than conventional mice 
and rats. Also the fact that no other organisms are present makes the model less 
like the situation in humans. Germ-free experiments using aged mice have been 
performed as a model of elderly infection with C. difficile in humans. One study 
found that aged (7-9 month old) germ-free C57BL/6 mice were susceptible to 
severe CDI and provided a useful model to elucidate the host immune response 
to acute CDI (121).   
When conventional mice are infected directly with C. difficile they are not 
readily susceptible to CDI. It is only after their normal indigenous microbiota is 
disrupted by antibiotic use do they become susceptible to infection (28, 67, 130).  
A murine model of C. difficile infection was reported where pre-treatment of mice 
with multiple antibiotics rendered mice susceptible to C. difficile colonization and 
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the development of colitis (28). Results from this model closely mimicked 
important aspects of human infection including varied disease severity, response 
to antibiotic treatment directed against C. difficile and the development of 
recurrence. In this model, mice were pre-treated with a cocktail of five antibiotics 
(colistin, kanamycin, gentamicin, metronidazole and vancomycin) administered in 
drinking water for three days, followed by a two-day period of time without 
antibiotics (28). Animals then received a single intra-peritoneal dose of 
clindamycin followed by the administration of C. difficile via oral gavage one day 
later. Only animals that received both the preconditioning antibiotic cocktail and a 
dose of clindamycin were susceptible to disease (28, 130).  
Other mouse models of CDI have since been published. Some 
researchers have adapted the five-antibiotic with clindamycin model to study CDI 
recurrence – a continuing problem with many recovering C. difficile infected 
patients (155). In the recurrence model, mice surviving the first round of pre-
treatment with the five-antibiotic cocktail and clindamycin followed by C. difficile 
challenge were allowed to recover for 30 days. Afterwards, these mice were 
retreated with the five-antibiotic mixture and clindamycin and re-challenged with 
C. difficile (155). These types of studies make it possible to examine the host 
immune system in response to C. difficile infection. Jump and colleagues utilized 
a different mouse model to assess the effect of the antibiotic tigecycline on the 
establishment of in vivo colonization by using spores from a non-toxigenic C. 
difficile strain (75). In that study CD-1 mice were given subcutaneous tigecycline, 
clindamycin, or both antibiotics for 5 days. On day two of antibiotic treatment, 
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mice were administered C. difficile spores by oral gavage. Results from this 
model showed that mice given clindamycin had high levels of C. difficile in feces 
compared to mice given tigecycline (75). 
 Many patients on immunosuppressive therapy develop C. difficile 
infections in hospitals. As a result researchers have developed a mouse model to 
study the effect of immunosuppressive drugs on CDI development (76). In this 
mouse model Balb-C mice are treated for 7 days with cyclosporine then 
challenged with a toxigenic C. difficile strain. All mice were colonized for 7 days 
or throughout the duration of the experiment, however the level of histopathologic 
involvement was moderate (76).  
CDI primarily occurs following the ingestion of spores from the 
environment. Individuals infected with C. difficile usually shed spores back into 
the environment which contributes to its perpetual spread. Lawley and 
colleagues established a mouse model where they examined the super shedding 
state as well as aspects of innate immune signaling (90). In this model C57BL/6 
mice were treated with neomycin for 24 hours prior to oral gavage with C. 
difficile. They demonstrated that neomycin pre-treatment was not necessary to 
establish a carrier state. Clinically, treatment with antibiotics was the primary risk 
factor for CDI (174). To determine the effect of antibiotic treatment on the 
dynamics of C. difficile shedding, carrier mice were treated with clindamycin and 
by three days after antibiotic treatment, an increase in C. difficile spore shedding 
was observed. These investigators also examined the dynamics in host-to-host 
transmission. Naive (uninfected) mice were housed with either carrier mice or 
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super shedder mice after which the naïve mice were removed and treated with 
clindamycin for four days. Results demonstrated that super shedder mice 
promoted efficient host-to-host transmission while the carrier state did not (90). 
While some studies require multiple antibiotics for mice to become 
susceptible to CDI, Buffie and colleagues recently demonstrated that mice 
treated with clindamycin only and then challenged with C. difficile VPI 10463 
spores developed rapid onset of clinical CDI signs, had high C. difficile 
colonization and resulted in 50% mortality (23).  
1.12 Interactions between members of the GI microbiota and C. difficile  
Many in vitro and in vivo studies have investigated interactions between C. 
difficile and other bacterial species. Fitzpatrick and colleagues used the five-
antibiotic and clindamycin mouse model established by Chen and colleagues 
(28) to examine the usefulness of a spore forming strain of Bacillus coagulans to 
improve clinical signs of CDI in mice. In this study mice were inoculated daily with 
B. coagulans, before and during the antibiotic cocktail regimen prior to C. difficile 
challenge. These researchers reported prolonged survival and improvement in 
CDI signs such as diarrhea and histopathology in the colon (51).  
Over the years a number of in vitro studies have identified organisms that 
are capable of inhibiting C. difficile growth, toxin production or the ability of C. 
difficile to adhere to colonic epithelial cells. These studies have mainly focused 
on a number of different Lactobacillus species, yeast or E. coli species. For 
instance, studies have shown that Lactobacillus delbrueckii can inhibit the 
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cytotoxic effects and adhesion of C. difficile to Caco-2 cells (a human colonic 
epithelial cell line) (11). Additionally, another study investigated the antagonistic 
activity of 50 intestinal Lactobacillus species against 23 pathogenic C. difficile 
strains and found 22 strains that were antagonistic to all or some C. difficile 
strains tested. These investigators attributed this result to increased hydrogen 
peroxide and lactic acid production by the Lactobacillus strains (112). 
 Bifidobacteria are said to have beneficial effects in humans. Hopkins and 
colleagues investigated whether four different Bifidobacteria strains in 
combination could inhibit C. difficile growth in a chemostat model and found no 
antagonistic effect against C. difficile (67). Another study utilized the 
cyclosporine-induced C. difficile infection model in mice to examine the effects of 
Lactobacillus acidophilus in limiting CDI severity. This study demonstrated that L. 
acidophilus significantly reduced the level of inflammation and prolonged survival 
but did not significantly inhibit C. difficile growth (76).  
Many germ-free mouse models have previously been used to investigate 
the antagonistic effect of individual or groups of bacteria on colonization 
resistance against C. difficile. Itoh and colleagues inoculated germ-free Balb/C 
mice with either whole or treated feces in which only Clostridia survived prior to 
C. difficile challenge and noted a significant decrease in C. difficile growth (69). 
Other studies have di-associated germ-free mice with non-pathogenic E. coli and 
C. difficile and observed a decrease in C. difficile growth (185). The addition of 
hamster cecal contents to these di-associated mice further eliminated C. difficile 
from the mouse gut (185).  
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Similarly, other studies have colonized germ-free mice with bacteria from 
human feces, rats and hamster cecal contents and observed resistance to C. 
difficile colonization (129, 153). Other di-association studies have evaluated 
neonatal strains of E. coli and Bifidobacterium bifidum from humans to inhibit C. 
difficile growth and found that these strains significantly reduced levels of C. 
difficile cytotoxin but not C. difficile growth (31). No protection or C. difficile 
growth and cytotoxin inhibition were observed when germ-free mice were di-
associated with Streptococcus faecalis, Eubacterium species or Bacteroides 
species (31). Su and colleagues di-associated germ-free mice with a butyrate 
producer, Clostridium butyricum and found no inhibitory effect on levels of C. 
difficile growth. However other clinical factors were not evaluated in this model 
(153).  
 
1.13  Summary  
 The indigenous gut microbiota plays an important role in protecting the host 
against infection with C. difficile. Administration of antibiotics disrupts the gut 
microbiota allowing C. difficile to colonize and cause disease (1, 28, 178). Work 
performed in this thesis was aimed at examining the effect of antibiotic 
administration in contributing to C. difficile susceptibility and the role of specific 
members of the indigenous GI microbiota in contributing to colonization 
resistance against C. difficile. The goals of this thesis were: (i) to study the effect 
of the administration of different antibiotic regimens including (a) the five-
antibiotic cocktail with clindamycin (28), and (b) cefoperazone on the indigenous 
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GI microbiota; (ii) to identify changes within the GI microbial communities after 
antibiotic treatment that predispose wild-type mice to C. difficile infection; (iii) to 
isolate specific members of the murine indigenous GI microbiota that were 
possibly associated with C. difficile colonization resistance or susceptibility after 
antibiotic treatment (Lachnospiraceae and E. coli); (iv) to determine the direct 
effect of Lachnospiraceae and E. coli in conferring colonization resistance or 
susceptibility to C. difficile and disease development in germ-free mice.
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The interplay between microbiome dynamics and pathogen dynamics in a 
murine model of Clostridium difficile infection 
2.1 Introduction 
	  
 The GI tract of mammals is inhabited by a complex microbial community 
that plays a crucial role in maintaining gut homeostasis (13, 34). The GI tract 
microbiota performs a number of beneficial metabolic functions (69) and also 
aids in the normal development of the mucosal epithelium and maturation of the 
mucosal immune system (20-22, 58). The indigenous microbiota protects the 
host from colonization by potentially pathogenic organisms, a function that is 
termed colonization resistance (61). It has been hypothesized that following the 
successful colonization by a pathogen, the ultimate pathology depends on the 
interplay between the host, pathogen and the indigenous microbiota (57). Thus, 
the resident microbiota can potentially modulate the outcomes of any 
pathogen/host interaction. 
 C. difficile is a Gram-positive, toxin-producing bacterium first described in 
1935 as a commensal organism in the fecal microbiota of healthy newborn 
infants (17). It is currently the most common cause of health care-associated 
diarrhea and colitis and is responsible for significant morbidity and increased 
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health-care cost (12). Clostridium difficile infection (CDI) is associated with the 
use of broad-spectrum antibiotic therapy, increasing patient age, and 
hospitalization (13). In recent years, the appearance of an epidemic strain 
(BI/NAP1/027) with potentially increased virulence has prompted renewed 
interest in the pathogenesis and epidemiology of this bacterium (37, 47). 
Additionally, it appears that the overall incidence of C. difficile infection has been 
increasing (27).  
 As C. difficile is not normally a significant component of the GI tract 
microbiota of adult humans, it is proposed that the indigenous gut microbiota is 
important in mediating colonization resistance against this pathogenic bacterium 
(44, 64). According to this hypothesis, disruption of the indigenous gut microbiota 
by the administration of antibiotics results in a decrease in colonization 
resistance. Furthermore, recurrent CDI appears to occur in the setting where the 
indigenous microbiota is sufficiently disturbed so that colonization resistance 
cannot be restored even after cessation of the inciting antibiotics and completion 
of specific treatment directed against C. difficile (35). We have demonstrated that 
patients with recurrent C. difficile infection have decreased diversity of the 
indigenous gut microbiota which may reflect a corresponding defect in 
colonization resistance (7). 
 A number of animal models have been developed to facilitate the study of 
C. difficile pathogenesis. The hamster model has been used extensively and it 
was in this host that Koch’s postulates were fulfilled for C. difficile as the 
causative agent of antibiotic-associated colitis (3). In this model colitis develops 
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after exposure to clindamycin and subsequent C. difficile challenge. However, 
the resulting disease is severe and lethal within three days after initial infection. 
This does not represent the usual course and spectrum of CDI in humans, which 
can range from asymptomatic to severe colitis (27). Furthermore, the limited 
availability of reagents to study host responses in hamsters has dampened the 
usefulness of this model. Germ-free mice challenged with C. difficile also develop 
intestinal disease but this model precludes an examination of the role of 
indigenous microbiota in mediating colonization resistance (41, 45, 65). Thus, the 
available animal models have limited studies of C. difficile pathogenesis. 
 It has been reported that treatment of mice with various antibiotics can 
render the animals susceptible to C. difficile colonization (30). In some cases this 
can lead to the development of colitis (8, 23). In this present study, I utilized 
antibiotic-treated mice to demonstrate that altering the community structure of the 
indigenous gut microbiota is associated with both the loss of colonization 
resistance against C. difficile and differences in the severity of disease. Our 
results indicate that a better understanding of the role of the indigenous 
microbiota in CDI could lead to novel and improved mechanisms for prevention 
and treatment. 
2.2 Methods 
2.2.1 Ethics statement 
 All animal protocols used during the conduction of these experiments were 
reviewed and approved by the University Committee on Use and Care of Animals 
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of the University of Michigan, Ann Arbor (protocol number 10212). The protocol 
was reviewed following guidelines for the care and use of laboratory animals set 
by the Office of Laboratory Animal Welfare, United States Department of Health 
and Human Services. 
2.2.2 Animals and housing 
The infection studies were performed with wild-type C57BL/6 mice from a 
breeding colony established using animals purchased from Jackson 
Laboratories. Mice were housed with autoclaved food, bedding and water. Cage 
changes were performed in a laminar flow hood. Animals experienced a cycle of 
12 hr of light and 12 hr of darkness. 
2.2.3 C. difficile growth conditions 
 The reference strain of C. difficile, strain VP1 10463 (ATCC 43255) was 
obtained and cultured on brain heart infusion agar containing 5% cysteine. An 
anaerobic environment was maintained at all times using an anaerobic chamber 
(Coy Industries). An incubation temperature of 37°C was used for growth. C. 
difficile suspensions for animal challenge were prepared by inoculating a single 
colony of C. difficile from a culture plate into brain heart infusion (BHI) broth, 
containing 5% cysteine, and allowing for overnight growth. Cells were harvested 
by centrifugation (5,000 rpm for 15 min) and washed three times with pre-
reduced PBS, pH 7.4. Bacterial enumeration was done to ensure that the correct 
dose of C. difficile vegetative cells was reached at the time of challenge.  
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2.2.4 Antibiotic administration and infection with C. difficile 
Mice were divided into treatment groups consisting of 5 to 8 animals that were six 
to eight weeks old. An antibiotic mixture of kanamycin (0.4 mg/mL), gentamicin 
(0.035 mg/mL), colistin (850 U/mL), metronidazole (0.215 mg/mL), and 
vancomycin (0.045 mg/mL) was prepared in sterile drinking water (8). Antibiotics 
were purchased from Sigma-Aldrich (cat# K1377, G1914, C4461, M1547, V2002, 
C5269, and C4292). The antibiotic cocktail was administered for 3 days then the 
animals were switched to regular autoclaved drinking water for 2 days. All mice in 
each experiment were housed under the same conditions and were fed standard 
autoclaved chow.  A single dose of clindamycin (10 mg/kg) was administered 
intraperitoneally one day before C. difficile challenge. Cefoperazone (0.5mg/ml) 
was prepared in sterile drinking water and administered for 10 days. The 
cefoperazone drinking water was replaced with a fresh supply every 48 hours for 
the duration of cefoperazone administration. Animals were then switched to 
regular autoclaved drinking water for 2 days. A single dose of clindamycin (10 
mg/kg) was administered intraperitoneally one day before C. difficile challenge. 
Some animals were allowed to recover for 6 weeks after cefoperazone treatment 
then a single dose of clindamycin was administered prior to C. difficile infection. 
Animals were infected by oral gavage with 1 x 105 CFU of C. difficile strain VPI 
10463. Animals were monitored daily for signs of disease such as diarrhea, 
hunched posture and weight loss. 
 
                                     62 
2.2.5 Necropsy and histological procedures 
 Mice were euthanized by CO2 asphyxiation. The tip of the cecum of each mouse 
was removed, halved, and rinsed in phosphate-buffered saline to remove luminal 
contents. Approximately 5 mm of proximal colon and terminal ileal tissue and 
luminal contents were collected from each animal. All samples were snap frozen 
in liquid nitrogen and stored at -80°C. The remaining cecum, colon and ileal 
tissue were placed intact into histology tissue cassettes and stored in 10% 
buffered formalin for 24 hours then transferred to 70% ethyl alcohol (70). Tissue 
cassettes were then processed, paraffin embedded and then sectioned. 
Haematoxylin and eosin stained slides were prepared for histologic examination 
(McClinchey Histology Lab Inc.).  
2.2.6 Histopathologic examination 
Histological slides were coded, randomized, and scored in a blinded manner by a 
board-certified veterinary pathologist. A scoring system was adapted from a 
previously published method (8, 26). Edema, cellular infiltration and epithelial 
damage in each tissue (colon, cecum, ileum) were scored from 0-4 according to 
the following defined criteria: Edema scores – 0: no edema; 1: mild edema with 
minimal (<2x) multifocal submucosal expansion; 2: moderate edema with 
moderate (2-3x) multifocal sub-mucosal expansion; 3: severe edema with severe 
(>3x) multifocal sub-mucosal expansion; and 4: same as score 3 with diffuse 
sub-mucosal expansion. Cellular infiltration scores were graded as follows: 0: no 
inflammation; 1: minimal multifocal neutrophilic inflammation; 2: moderate 
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multifocal neutrophilic inflammation (greater submucosal involvement); 3: severe 
multifocal to coalescing neutrophilic inflammation (greater submucosal +/- mural 
involvement; and 4: same as score 3 with abscesses or extensive mural 
involvement. Epithelial damage was scored as follows: 0: no epithelial changes; 
1: minimal multifocal superficial epithelial damage (vacuolation, apoptotic figures, 
villus tip attenuation/necrosis); 2: moderate multifocal superficial epithelial 
damage (vacuolation, apoptotic figures, villus tip attenuation/necrosis); 3: severe 
multifocal epithelial damage (same as above) +/- pseudomembrane (intraluminal 
neutrophils, sloughed epithelium in a fibrinous matrix); and 4: same as score 3 
with significant pseudomembrane or epithelial ulceration (focal complete loss of 
epithelium). 
2.2.7 DNA extraction 
Total DNA from fecal and tissue samples was extracted using the MagNA Pure 
DNA isolation protocol (Roche, cat# 03730964001). Samples were placed in a 
Ultra Clean fecal bead tube (MoBio) to which 500 µl of MagNa Pure bacterial 
lysis buffer (Roche) was added. Samples were bead beaten for 1 min with a mini 
bead beater (Biospec), digested with proteinase K, incubated at 65°C, bead 
beaten for 1 min and then was heat inactivated at 95°C. Samples were placed in 
the MagNa Pure (Roche) and the MagNa Pure nucleic isolation kit protocol for 
bacterial DNA was followed as recommended by the manufacturer. 
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2.2.8 Construction of 16S ribosomal rRNA-encoding gene clone libraries 
The community structure of infected and uninfected mice was analyzed by the 
construction of 16S rRNA gene clone libraries (42, 43). PCR targeting bacterial 
16S rRNA genes using primers 8F (5’-AGAGTTTGATCCTGGCTCAG-3’) and 
1492R (5’-GGTTACCTTGTTACGACTT-3’) (55) was performed on each 
extracted DNA sample. PCR was performed using Illustra Pure Taq Ready-To-
Go PCR beads (GE Healthcare, cat# 27955901). Reaction mixtures were set up 
with 100 ng of template DNA, 20 pmol of each primer, and water to a total volume 
of 25 µl. The reaction mixtures were subjected to amplification in a DNA thermal 
cycler (Eppendorf Mastercycler gradient) with the following cycling conditions: 
initial denaturation at 94°C for 2 min followed by 20 cycles of denaturation at 
94°C for 30 sec, annealing at 58°C for 45 sec, and extension at 72°C for 1.5 min. 
A final extension at 72°C for 10 min was performed. Control amplifications with 
sterile water were included in each amplification reaction and never gave visible 
amplicons. Amplicons were purified using a kit Illustra MicroSpin Column (GE 
Healthcare, cat# 27514001) according to the recommendations of the 
manufacturer. The purified PCR products were ligated into a plasmid vector (pCR 
2.1; Invitrogen). 
2.2.9 DNA sequencing and analysis 
Plasmid purification and DNA sequence determination of 96 randomly selected 
clones from each library were performed by the DNA Sequencing Core facilities 
at the University of Michigan. Each clone was sequenced with a single primer 
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(8F) that typically yielded 750 bases of readable sequence. Sequences with 
numerous ambiguous base calls or with fewer than 350 total bases were 
excluded from further analysis. Sequences were analyzed for the formation of 
chimeras using the Chimera Check program from the Ribosomal Database 
Project (9). Potential chimeric sequences were excluded from additional analysis. 
Sequences were also aligned to a phylogenetically diverse collection of 16S 
rRNA gene sequences using the RDP Classifier (9). Partial 16S rRNA sequences 
were initially analyzed using mother (54) to calculate pair wise Morisita-Horn 
distances which was exported to Mega4 (28) software package and then UPGMA 
analysis was used to create dendrograms.  
2.2.10 Quantitative PCR 
 Quantitative PCRs were used to assay the quantity of rRNA operons in the DNA 
samples relative to a single-copy host gene (mouse tumor necrosis factor alpha 
[TNFa]) as detailed in Antonopoulos et al (1). Assays used the LightCycler 480 
Probes Master reaction mixture (Roche, cat# 04707494001) at 1x concentration 
and appropriate primer-probe sets to increase the specificity of the signals 
detected from the sample DNA (100 ng). For detection of the bacterial signal, 100 
nmol of each of the forward and reverse primers and the flourescent probe were 
included in the reaction mixtures. Sequences for the forward primer (5'-
TCCTACGGGAGGCAGCAGT-3'), the reverse primer (5'-
GGACTACCAGGGTATCTAATCCTGTT-3'), and the probe (5'-[6-
carboxyfluorescein]-CGTATTACCGCGGCTGCTGGCAC- [6-
carboxytetramethylrhodamine]-3') were based on the work of Nadkarni et al (38). 
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Signals were detected with a LightCycler 480 instrument (Roche). Detection of 
the host signal used 200 nmol of the forward (TNFa_mu_se; 5'-
GGCTTTCCGAATTCACTGGAG-3') and reverse (TNFa_mu_as; 5'-
CCCCGGCCTTCCAAATAAA-3') primers and 100 nmol of the probe 
(TNFa_mu_probe; 5'-Cy5-ATGTCCATTCCTGAGTTCTGCAAAGGGA-Iowa 
Black RQ-3') adapted from Nitsche et. al. (40). Relative bacterial loads were 
compared via the CT method by normalizing the 16S rRNA gene signal to the 
host signal (56). 
2.2.11 Monitoring C. difficile colonization 
The colonization status of C. difficile infected animals was monitored using a C. 
difficile toxin multiplex qPCR assay of fecal pellets collected at various time 
points pre and post challenge from mice in each group. For the C. difficile Toxin 
Multiplex qPCR (LightCycler 480) 8 and 10 pmol/µl for tcdA and tcdB primers, 
respectively, were prepared from 200 pmol/µl original stocks. Primer and probe 
sets are as follows: tcdA_F: 5’-GGTAATAATTCAAAAGCGGCT, tcd_R: 5’-
AGCATCCGTATTAGCAGGTG, tcdA_probe_FAM: 5’-6FAM-
AGCCTAATACAGCTATGGGTGCGAA-BHQ1, tcdB_F: 5’-
GAAAGTCCAAGTTTACGCTCAAT, tcdB_R: 5’-GCTGCACCTAAACTTACACCA, 
tcdB_probe_Hex: 5’-Hex-ACAGATGCAGCCAAAGTTGTTGAATT-BHQ1 (James 
Versalovic, personal communication, manuscript in preparation). For each 20 µl 
reaction, 4 µl template, 10 pmol tcdA primers, 12.5 pmol tcdB primer, 1.6 pmol 
tcdA probe and 2 pmol tcdB probe were used. The following cycling conditions 
were used for the qPCR run: Activation - 95°C for 15min, 95°C for 15sec, Cycling 
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(X45) - 60°C for 20sec, 72°C for 10sec, Hold - 37°C for 30sec. Values were 
normalized to mouse TNF alpha gene content and the mean fold change of tcdA 
tcdB gene content were calculated using the 2-ΔCt method (56). 
2.2.12 Measurement of RegIIIγ  expression 
 Total nucleic acid was isolated from mouse ileal tissue using the MagNA Pure 
Compact Nucleic Acid isolation kit (Roche). Samples were deoxyribonuclease 
(Roche) treated and then reverse transcribed using the RT2 First Strand kit (SA 
Biosciences) to yield cDNA for real-time PCR analysis. SYBR Green-based real-
time PCR was performed on a LightCycler 480 instrument (Roche) using RegIIIγ-
specific primers (forward primer: 5’-TTCCTGTCCTCCATGATCAAAA; reverse 
primer: 5’-CATCCACCTCTGTTGGGTTCA) from Cash et al. (6). Control 
experiments were performed to establish that amplicons were derived from cDNA 
and not from genomic DNA or primer-dimers. Relative levels of RegIIIγ were 
compared via the CT method by normalizing to mouse GAPDH (Roche) (56). 
2.2.13 C. difficile cytotoxin assay 
The assay was performed in 96-well flat-bottom microtiter plates (Corning) and 
was adapted from Corthier et al (10). Green African monkey kidney epithelial 
cells (Vero) (provided by M. Imperiale, University of Michigan) were grown to 
confluency in DMEM (GIBCO Laboratories, cat# 11965) containing 10% heat 
inactivated fetal bovine serum (GIBCO Laboratories, cat# 16140) and 1% 
penicillin streptomycin solution (GIBCO Laboratories, cat# 15140). The cells 
were trypsinized using 0.25% trypsin (GIBCO Laboratories, cat# 25200) and 
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washed with 1 volume of DMEM medium. Cells were diluted in DMEM medium 
and approximately 1x105 cells were distributed per well and incubated at 37°C 
with 5% CO2 for 18-24 hours. Samples of luminal contents or intestinal tissue 
were weighed and 500 µl of 1x PBS was added. Intestinal tissue was 
homogenized using a Medimachine (Becton Dickenson). Samples were vortexed 
then spun at 13,000 rpm for 5 minutes and then the supernatant was filtered 
through a 0.2 µm membrane. Each sample was titrated in two-fold dilutions within 
the wells to a maximum dilution of 2-12 and each well had a corresponding control 
to which both antitoxin (TechLabs, cat# T5000) and sample were added. After an 
overnight incubation at 37°C, plates were fixed with 10% buffered formalin for 2 
hours then stained with geimsa (50 µl per well) for 15 minutes followed by a wash 
with 1x PBS. Wells with approximately 100% round cells were easily recognized 
under 200x magnification. The cytotoxic titer was defined as the reciprocal of the 
highest dilution that rounds 100% of Vero cells per gram of sample. Vero cells 
with purified C. difficile toxin and antitoxin (TechLabs, cat# T5000) were used as 
controls. 
2.2.14 Statistical analysis 
Statistical analyses were performed using Prism 5 for Mac OS X GraphPad 
Software. t tests were used for treatment group comparisons, except for 
categorical histology scores, where the nonparametric Krustal Wallis test was 
used. Statistical significance was set at a P value of <0.05. 
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2.3 Results 
2.3.1 Overcoming colonization resistance to C. difficile 
 To compare the ability of different antibiotic regimens to overcome 
colonization resistance against C. difficile, six to eight week old C57BL/6 mice 
were treated with either an antibiotic cocktail (kanamycin, gentamicin, colistin, 
metronidazole, and vancomycin), clindamycin or the combination of both prior to 
challenge with 1 x 105 CFU of C. difficile (VPI 10463) via oral gavage (Figure 
2.1A, 2.1B). Control animals were challenged with C. difficile in the absence of 
any antibiotic pretreatment. Colonization was monitored by culture and C. 
difficile-specific PCR was performed on DNA isolated from stool pellets or from 
gut tissue harvested at necropsy, which occurred 2 to 4 days post-challenge. 
Animals were monitored daily for the signs of clinical CDI including diarrhea, 
weight loss and hunched posture. C. difficile was never recovered from animals 
that were challenged without antibiotic pretreatment. Animals that received the 
antibiotic cocktail without clindamycin prior to C. difficile challenge were also 
resistant to colonization. Of the 9 animals that received only a single dose of 
clindamycin prior to C. difficile challenge, 4 of them shed low amounts of the 
organism in their feces for the first 2 days following challenge, but the organism 
was no longer detectable in stool or tissue when the animals were euthanized 
four days following challenge. All 12 animals that received both the antibiotic 
cocktail and clindamycin prior to C. difficile challenge shed the organism in their 
feces throughout the experiment and C. difficile was found in tissue at the time of 
necropsy. These results indicate that the combination of the antibiotic cocktail 
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and clindamycin is required to completely overcome colonization resistance 
against C. difficile.  
 
Figure 2.1 Experimental designs for alteration of microbiota and C. difficile 
infection. Wild-type mice were treated with: (A) a single intraperitoneal dose of 
clindamycin and challenged with 105 CFU of C. difficile (VPI 10463) (B) a 5 
antibiotic cocktail in drinking water for 3 days; a 5 antibiotic cocktail in drinking 
water for 3 days followed by a 2-day period without the drug and a single dose of 
clindamycin; or a 5 antibiotic cocktail in drinking water for 3 days followed by a 2-
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day period without the drug and a single dose of clindamycin followed by 
challenge with 105 CFU of C. difficile one day later (C) 10 days cefoperazone 
treatment followed by 2 days off drug with or without C. difficile challenge (D) 10 
days cefoperazone treatment followed by 2 days off drug, a single dose of 
clindamycin followed by one day recovery with or without C. difficile challenge (E) 
10 days cefoperazone treatment followed by 6 weeks off drug, a single dose of 
clindamycin followed by one day recovery prior to C. difficile challenge (F) 10 
days cefoperazone treatment followed by 6 weeks off drug then C. difficile 
challenge.  
2.3.2 Clinical disease in C. difficile infected mice 
We monitored the development of disease in mice that received both the 
antibiotic cocktail and clindamycin prior to C. difficile challenge. Five of 12 
animals that received both the antibiotic cocktail and clindamycin did not show 
overt clinical signs of CDI despite remaining colonized with C. difficile. The 
remaining seven mice exhibited signs of disease including diarrhea, hunched 
posture and significant (>20% from baseline) weight loss (Figure 2.2). One 
animal was found dead at 2 days post challenge while six animals were 
moribund and euthanized 2 to 4 days post challenge. 
 
Figure 2.2  Weight loss in C. difficile infected mice. Weight loss curves for 
untreated (control) animals (n=5), and animals treated with the 5 antibiotic 
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cocktail for 3 days (days -6 to -3) then given a single dose of clindamycin after 2 
days off antibiotics followed by challenged with C. difficile one day later (n=11). 6 
of 11 mice lost >20% body weight (sick) while one animal died 1-2 days post 
challenge (not shown). The remaining 5 animals did not lose significant body 
weight (well) when compared to control animals. Weight loss percentage is 
based on the starting weight at day -6 with thick lines showing the average for 
animals in each clinical group and dotted lines showing the data for each 
individual. CDI- C. difficile infection 
 
A central feature of the pathogenicity of C. difficile is the production of two 
large glucosyltransferase toxins encoded by tcdA and tcdB that modify and 
inactivate the small GTPases Rho, Rac, and Cdc42 (63). We measured the 
activity levels of C. difficile toxin in the gut using a tissue culture cytotoxin assay. 
High levels of C. difficile cytotoxin were detected in samples obtained from 
animals with severe clinical disease (Figure 2.3A). Additionally, quantitative PCR 
analysis indicates that animals with severe clinical disease had significantly 
higher numbers of C. difficile in their gut at the time of necropsy compared to 
those animals that were clinically well (Figure 2.3B). These results suggest that 
the animals that did not develop severe CDI in the multi-antibiotic treatment 
protocol had the ability to control the population size of colonizing C. difficile and 
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Figure 2.3  Increased cytotoxin activity and C. difficile load are associated with 
increased CDI severity. (A) Vero cell tissue culture was used to determine the 
log10 reciprocal cytotoxin dilution per gram of sample. Each point represents 
individual animals that were either sick (n=5) or well (n=5) after treatment with 
antibiotics/clindamycin and exposure to C. difficile. Sick animals had increased 
levels of cytotoxin production compared to animals with less clinical disease. (B) 
Quantitative PCR was performed on cecal DNA from animals treated with 
antibiotics/clindamycin and exposed to C. difficile. Values represent the relative 
abundance of the tcdA gene normalized to the single copy mouse tumor necrosis 
factor α (TNFα) gene. Sick animals (n=6) had increased levels C. difficile 
compared to well animals (n=5) with less clinical disease. 
 
Histopathologic changes were seen in both the cecal and colonic tissue of all 
animals that received the antibiotic cocktail, clindamycin and C. difficile. 
Pathologic changes consisted of neutrophilic inflammation in the mucosa and 
submucosa with varying degrees of submucosal edema (Figure 2.4). Of note, 
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inflammation and, particularly, submucosal edema than animals that were 
infected but remained clinically well (Figure 2.4E, 2.4F). In the most severely 
affected animals, there were areas of erosion and in rare cases, ulceration. 
Occasionally, severely affected animals had luminal exudates comprised of 
degenerate neutrophils, hemorrhage, and sloughed epithelium embedded in a 
fibrinous matrix suggestive of pseudomembranes (Figure 2.4D). Untreated 
animals or those that received antibiotics without C. difficile challenge had no 
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Figure 2.4  Animals with clinically severe CDI have increased colonic 
histopathology. Proximal colon of an untreated (control) mouse. HE. Original 
magnification x40. (B) Colon of a sick antibiotic treated mouse infected with C. 






















































                                     76 
Increased magnification of colon from a well antibiotic treated mouse infected 
with C. difficile showing moderate neutrophilic mucosal and submucosal 
inflammation but lacking significant submucosal edema. HE. Original 
magnification x200. (D) Sick C. difficile infected mouse showing marked 
submucosal edema in addition to neutrophilic inflammation. There is also a 
pseudomembrane on the luminal surface consisting of degenerate neutrophils, 
sloughed epithelial cells, and hemorrhage within a fibrinous matrix. HE. Original 
magnification x200. (E) Categorical cellular infiltration scores of untreated 
(control) animals, C. difficile infected well animals, and C. difficile infected sick 
animals. (F) Categorical edema scores of untreated (control) animals, C. difficile 
infected well animals, and C. difficile infected sick animals. Comparisons 
between groups were performed using the nonparametric Krustal Wallis test. 
2.3.3 C. difficile colonization resistance is independent of RegIIIγ  
expression levels 
	  
 RegIIIγ is a secreted C-type lectin with potent bactericidal activity against 
Gram-positive bacteria (6). It binds the surface-exposed peptidoglycan layer of 
Gram-positive organism with high affinity in a calcium-independent manner (33). 
Expression of RegIIIγ appears to be driven by the indigenous gut microbiota 
through host sensing of microbial-associated molecular patterns, primarily from 
Gram-negative organisms. RegIIIγ has been shown to be important in mediating 
colonization resistance to vancomycin resistant Enterococcus (VRE) (5). 
Treatment with antibiotics is associated with decreased expression of RegIIIγ and 
susceptibility to colonization with VRE. We used quantitative PCR to examine the 
role of RegIIIγ in mediating colonization resistance in the murine model of CDI. 
RegIIIγ expression was decreased 50 fold in animals treated with the antibiotic 
cocktail compared to the untreated group (Figure 2.5). Clindamycin treatment 
alone did not alter RegIIIγ expression, but when preceded by treatment with the 
antibiotic cocktail, clindamycin treatment was associated with significantly 
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decreased expression levels. Interestingly, animals that developed severe clinical 
disease after treatment with the antibiotic cocktail and clindamycin prior to 
challenge with C. difficile had a significant (6-fold) increase in RegIIIγ compared 
to the untreated controls while this increase was not seen in animals that were 
clinically well. 
  
Figure 2.5  C. difficile colonization is not correlated with RegIIIγ expression  
RegIIIγ mRNA expression levels in ileal tissue from animals in the untreated 
(control) (n=5), antibiotics (n=3), clindamycin  (n=5), antibiotics/clindamycin 
(n=4), antibiotics/clindamycin/C. difficile (well) (n=5), and antibiotics/ clindamycin/ 
C. difficile (sick) (n=6) treatment groups. Values were normalized to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression and the mean 
fold expression of RegIIIγ relative to the untreated group ± standard deviation is 
plotted. The antibiotic cocktail as well as antibiotics/clindamycin are associated 
with decreased RegIIIγ expression but not clindamycin only. Sick animals 
pretreated with antibiotics/clindamycin and exposed to C. difficile had a 
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2.3.4 Shifts in microbial ecology associated with antibiotic treatment and C. 
difficile infection 
We have previously shown that antibiotic administration can decrease the 
overall mass of bacteria within the gut (1). The administration of the five antibiotic 
cocktail significantly decreased the overall bacterial population by 20-fold when 
measured immediately after the treatment period (Figure 2.6A). However, a 
single administration of clindamycin did not change the total microbial population 
size when measured 24 hours after the dose was given (Figure 2.6A). 
Furthermore, following administration of both the antibiotic cocktail and 
clindamycin, at the time corresponding to C. difficile challenge, the overall 
bacterial population size was similar to untreated animals (Figure 2.6A). 
Therefore, the loss of colonization resistance against C. difficile following 
antibiotic administration was not directly related to changes in the overall density 
of the gut microbiota. 
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Figure 2.6  C. difficile colonization is not correlated with overall levels of the 
indigenous microbiota. (A and B) Total 16S rRNA-encoding gene quantitative 
PCR was performed on cecal DNA from animals treated as (A) untreated (n=6), 
5-antibiotics (n=7), clindamycin (n=5), and 5-antibiotics/clindamycin (n=4). 
Bacterial load was decreased after treatment with the antibiotic cocktail but 
remained unchanged after treatment with clindamycin alone or treatment with 
both the antibiotic cocktail and clindamycin when compared to controls. (B) 
untreated (n=3), cefoperazone (n=4), cefoperazone and clindamycin (n=4), 
cefoperazone with 6 weeks recovery (n=4) and cefoperazone with 6 weeks 
recovery followed by a dose of clindamycin (n=4). Bacterial load was severely 
decreased following cefoperazone treatment with a 2-day recovery period but 
recovered after clindamycin was administered a day later and remained 
unchanged after a 6-week recovery period. Values were normalized to host DNA 
content as described in the methods and the mean fold change of 16S rRNA 
gene expression relative to the controls ± standard deviation is plotted. Group 
comparisons were performed using Krustal Wallis. (* P= <0.05, *** P= <0.0001) 
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Since the loss of colonization resistance against C. difficile was not 
associated with an overall decrease in bacterial density, we analyzed 16S rRNA 
gene sequences retrieved from gut tissue at the time of necropsy to examine the 
specific changes in the community structure of the gut microbiota that resulted 
from antibiotic treatment and C. difficile infection. In control mice that never 
received antibiotics, the gut microbial community was dominated by members of 
the phylum Firmicutes with lower numbers of Bacteroidetes. The administration 
of either the antibiotic cocktail, clindamycin or both resulted in a significant 
change in the structure of the gut microbial community (Figure 2.7A, 2.7B). The 
administration of the antibiotic cocktail resulted in a shift in the community 
structure to one dominated by bacteria from the family Lactobacillaceae. 
Clindamycin treatment alone shifted the community composition to a dominance 
of Proteobacteria belonging to the family Enterobacteriaceae (Figure 2.7A). 
When clindamycin was administered following treatment with the antibiotic 
cocktail, there was again a predominance of Proteobacteria in the gut community 
(Figure 2.7B).  
 Interestingly, subsequent changes in the gut microbial community 
structure following C. difficile challenge followed two distinct courses. Animals 
that developed severe clinical disease harbored a gut microbial community at the 
time of necropsy that remained dominated by Proteobacteria (Figure 2.7B). 
Animals that remained clinically well and had significantly less severe histologic 
colitis at the time of necropsy possessed a gut microbiota that appeared to be 
returning towards the baseline state. Members of the Firmicutes again became 
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significant members of the community and Proteobacteria were no longer 
dominant. 16S rRNA gene sequences corresponding to C. difficile were detected 
in the gut communities of both clinically well and sick animals but in agreement 
with the quantitative PCR results, C. difficile sequences composed 8.5% (± 7.7) 
of those recovered in clinically ill mice, but only 1.1% (± 1.5) of the sequences in 
well mice. Thus, mice that were clinically well harbored an indigenous microbial 
community that was more similar to the baseline state seen in untreated controls 
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Figure 2.7  Shifts in microbial community structure and composition associated 
with antibiotic administration and C. difficile infection. The community structure of 
the gut microbiota was determined by 16S rRNA gene clone library construction. 
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cocktail (abx) or with clindamycin alone (clinda) were altered from that seen in 
untreated controls. The antibiotic cocktail alone resulted in the appearance of 
significant numbers of lactobacilli, whereas clindamycin administration was 
associated with an increase in Proteobacteria. (B) The microbial communities in 
animals that received the combination of the antibiotic cocktail and clindamycin 
were also dominated by Proteobacteria. Animals that were challenged with C. 
difficile after antibiotic treatment harbored gut communities that were 
distinguished by the clinical disease that developed. Proteobacteria dominated 
sick antibiotic treated animals exposed to C. difficile while the communities of 
animals that remained well appeared to resemble controls with a predominance 
of Firmicutes. Dendrograms were constructed using Morisita-Horn community 
similarities based on >97% sequence similarity while taxonomic assignments 
were made using the Ribosomal Database Project Classifier. antibiotic cocktail- 
abx, clindamycin- clinda, C. difficile- C.diff 
 
2.3.5 Cefoperazone treatment renders mice susceptible to colonization and 
colitis following C. difficile challenge 
We previously demonstrated that administration of the beta-lactam 
antibiotic cefoperazone had significant and long-lasting effects on the indigenous 
gut microbiota (1). Even after a six-week recovery period following a 10-day 
course of cefoperazone, the gut microbiota exhibited altered community structure 
and diminished diversity. The 5 antibiotic cocktail did not have such long-lasting 
effects as gut microbial composition returned to baseline within four weeks of 
discontinuing the drug (data not shown). 
To determine if the greater disturbance of the gut microbiota associated 
with cefoperazone administration differentially altered the course of experimental 
C. difficile infection, six to eight week old C57BL/6 mice were treated with 
cefoperazone prior to oral challenge with C. difficile. One group of mice received 
cefoperazone in drinking water for 10 days followed by a 2-day period on plain 
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water (Figure 2.1C). Another group received the same cefoperazone treatment 
followed by a single dose of clindamycin after 2 days (Figure 2.1D). Two final 
groups received 10 days of cefoperazone followed by a 6-week period without 
the drug with or without a single dose of clindamycin (Figure 2.1E, F). All four 
groups of animals then received a challenge of 1 x 105 CFU of C. difficile via oral 
gavage. All animals in the 2 groups of mice that were challenged 2-3 days after 
cefoperazone treatment (with or without clindamycin) were moribund by 2 days 
post challenge while one animal died between 1-2 days post challenge. High 
levels of C. difficile were present in these animals (Figure 2.8). Similarly, all 
animals treated with cefoperazone followed by a 6-week recovery period that 
received a single dose of clindamycin and C. difficile challenge also exhibited 
signs of CDI and were moribund by 4 days post challenge. However, animals 
that were challenged with C. difficile after the 6-week recovery period without a 
dose of clindamycin were not colonized (Figure 2.8). 
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Figure 2.8  Increased C. difficile load after cefoperazone treatment. Quantitative 
PCR was performed on cecal DNA from animals treated with cefoperazone with 
or without clindamycin then exposed to C. difficile. Values represent the 
abundance of tcdA gene normalized to the single copy mouse tumor necrosis 
factorα (TNF α) gene. Animals treated with cefoperazone then infected with C. 
difficile 2 days later had very high levels of C. difficile (n=4). However C. difficile 
colonization following a 6-week recovery period only occurred after clindamycin 
treatment (n=4). All animals with detectable C. difficile levels succumbed to CDI. 
Cef- cefoperazone, Clin- clindamycin, C.diff- C. difficile, 6wk- 6-week recovery off 
cefoperazone.     
16S rRNA-encoding gene analysis on tissue collected from cefoperazone-
treated animals indicated that a 10-day treatment with this antibiotic resulted in a 
bacterial gut community dominated by bacteria in the family Pseudomonadaceae 
(Figure 2.9A). Following a 2-day period without cefoperazone and a single dose 
of clindamycin, the gut microbiota became dominated by members of the 
Lactobacillaceae (Figure 2.9A). After infection with C. difficile the communities of 
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dominated by C. difficile (Figure 2.9B) with between 48-92% (69 ± 15%) of the 
16S rRNA-encoding gene sequences retrieved corresponding to this organism. 
C. difficile 16S rRNA-encoding gene sequences were detected in 3 of the 4 
animals infected 6 weeks after cefoperazone treatment followed by a dose of 
clindamycin and C. difficile challenge (12.8 ± 10%). 
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Figure 2.9  Shifts in microbial community structure and composition associated 
with cefoperazone administration and C. difficile infection. The composition of the 
gut microbiota was determined by 16S rRNA clone library construction. (A) The 
microbial communities in animals that were treated with cefoperazone with or 
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after cefoperazone treatment, the communities returned to a community structure 
that resembled untreated controls. (B) Animals that were challenged with C. 
difficile within three days after stopping cefoperazone treatment (with or without 
clindamycin treatment) had very high relative levels of C. difficile in their microbial 
communities.  Animals that were challenged with C. difficile 6 weeks after 
antibiotic treatment was stopped followed by a single dose of clindamycin had 
less C. difficile present. The relative abundance of C. difficile appeared to directly 
correlate with the amount of Proteobacteria and inversely with the abundance of 
Lachnospiraceae. Dendrograms were constructed using Morisita-Horn 
similarities based on >97% sequence similarity while taxonomic assignments 
were made using the Ribosomal Database Project Classifier. cefoperazone- cef, 
clindamycin- clinda, C. difficile- C.diff 
 Given the apparent increased susceptibility to C. difficile infection after 
cefoperazone treatment, we determined if decreasing the challenge dose would 
alter the severity of the resultant CDI. Groups of 9 to10 animals were treated with 
a 10-day course of cefoperazone followed by a 2-day recovery period without the 
drug, and were then challenged with varying doses of C. difficile ranging from 2 x 
102 CFU to 2 x 105 CFU. The animals were monitored for weight loss and clinical 
signs of severe disease, and euthanized when the appropriate clinical endpoints 
were reached. There was a strict dose dependence on the rate at which clinical 
endpoints were reached (Figure 2.10). The majority of animals receiving the 
highest dose of C. difficile became moribund within 2 days post challenge while 
all of the animals receiving the lowest dose of 102 CFU remained clinically well 
until 5 days post challenge at which time all became ill and required euthanasia. 
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Figure 2.10  Dose dependence of disease in infected cefoperazone-treated mice 
infected with C. difficile. Kaplan-Meier survival plot for mice infected with different 
doses of C. difficile VPI 10463 (2 x 102, 2 x 103, 2 x 104, 2 x 105 CFU) after 10 
days of cefoperazone pretreatment and 2-day recovery. (n=9 for 102, 103 groups 
and n=10 for 104, 105 groups). Survival curves are significantly different 
(p=0.0123 by the Log-rank (Mantel-Cox) Test) and there is a significant trend 
(p=0.001). 
2.4 Discussion 
The term “colonization resistance” was coined to refer to the ability of an 
established gut microbial community to resist invasion by additional microbes 
(15, 19, 62). Although this initially applied to pathogenic microbes, the concept 
was derived from concepts of community robustness derived from studies of 
classical ecologic systems (for example grasslands and lakes) and thus could be 
applied to any invading microbe (52). Current hypotheses suggest that the 
normal indigenous microbiota is not permissive for the establishment of 
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colonized by C. difficile without overt clinical disease, it is further hypothesized 
that the normal indigenous microbiota can at least limit the production of toxin, 
perhaps by directly interfering with toxin production or limiting the population size 
of C. difficile and preventing significant amounts of toxin from accumulating in the 
gut (50, 64). Accordingly, disruption of the indigenous microbiota by antibiotics 
leads to a loss of colonization resistance, making the gut vulnerable to 
colonization by exogenous C. difficile spores or, in previously colonized patients, 
expansion and toxin production. In support of this concept, Wilson and 
colleagues provided evidence for the ability of the normal gut microbiota to inhibit 
C. difficile by demonstrating that administration of normal cecal homogenates 
would decrease the number of viable C. difficile and prevent colitis in antibiotic-
challenged hamsters (64, 66). 
Using a murine model of C. difficile infection involving pretreatment of 
mice with antibiotics to overcome colonization resistance, we found that 
administration of 105 CFU of C. difficile to animals treated with a cocktail of five 
antibiotics and clindamycin results in uniform colonization and a mortality rate of 
about 60%. The initial description of this model noted that by increasing the 
challenge dose of C. difficile, mortality would increase in direct relationship to the 
dose of organism (8). In the current study, we also found that a more significant 
disruption of the microbiota, using the antibiotic cefoperazone could also result in 
uniform mortality in animals that were challenged with a dose of C. difficile that 
was lethal to only about half the animals that were treated with the five antibiotic 
cocktail and clindamycin.  
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Although the combination of the antibiotic cocktail and clindamycin was 
able to overcome colonization resistance, it is important that neither alone had 
the same effect. Therefore, loss of colonization resistance is not simply 
associated with creating an overall “depauperate” community but is dependent 
on the specific changes to the community structure as well. Administration of the 
antibiotic cocktail alone significantly decreased the overall biomass of the 
community, but this decrease in bacterial community size alone did not lead to a 
loss of colonization resistance. Furthermore, after administration of the antibiotic 
cocktail and clindamycin, at the time of successful challenge with C. difficile, the 
overall bacterial population had recovered, but the community structure was 
markedly altered from baseline. This further supports the idea that the specific 
changes brought on by antibiotic administration determine susceptibility to C. 
difficile colonization. This is consistent with the clinical observation that the risk of 
subsequent CDI differs with different antibiotics (4) and in vitro and animal 
studies that also differentiate antibiotics on the basis of their ability to overcome 
colonization resistance against C. difficile (25, 39, 50). 
Taken together these results suggest that this murine infection model 
accurately represents competition between two opposing processes that are 
thought to be at the center of the pathogenesis of CDI (Figure 2.11). On one 
hand there is the expansion of the population of C. difficile once it has colonized 
an altered/susceptible microbial community and the subsequent production of 
toxin. On the other hand, there is the tendency of stable microbial communities to 
return towards their baseline state following a perturbation, in this case, antibiotic 
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administration (1, 11, 14, 52). According to this model, the observation of 50% 
mortality in animals treated with the antibiotic cocktail and clindamycin and then 
challenged with 105 CFU of C. difficile reflects a point at which the two processes 
are in close balance. In this case, if the pathogen can grow and produce toxin 
more rapidly than the recovery of the indigenous microbiota clinically severe 
disease would result. Alternately, if the microbiota recovers prior to sufficient 
expansion of C. difficile there could be control of the infection. This balance can 
be shifted in favor of C. difficile colonization and severe disease either by 
administering a larger challenge dose of C. difficile or causing a greater 
perturbation in the microbial community structure by administering cefoperazone. 
Alternately, administration of a smaller inoculum of C. difficile results in less 
disease. In terms of the antibiotic cocktail with clindamycin, decreasing the 
inoculum prevented the development of clinical disease, but in the setting of 
cefoperazone, this merely delayed the onset of disease. This further supports the 
idea that cefoperazone administration results in a greater disturbance of the 
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Figure 2.11  Model of the interaction between dynamics of the gut microbiota 
and C. difficile in antibiotic-treated mice. Antibiotic administration alters the 
community structure of the indigenous gut microbiota to a state that is 
susceptible to colonization with C. difficile. Subsequent clinical outcome is 
determined by the balance between the recovery of the gut microbiota following 
withdrawal of antibiotics and the expansion of the population of C. difficile and 
toxin production. 
Additionally, the overall gut bacterial load remained reduced two-days 
following the end of cefoperazone treatment. This community was able to 
rebound to baseline levels 24-hours later following a single administration of 
clindamycin. Regardless of the overall bacterial mass, all animals were moribund 
two days after C. difficile infection. This suggested that loss of colonization 
resistance against C. difficile was independent of the absolute load of the gut 
microbiota but dependent on specific alterations within the gut microbial 
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seemed to resemble that of untreated control animals which suggested that the 
gut community had recovered. Direct infection with C. difficile at this point 
resulted in no C. difficile colonization or disease development suggesting that the 
gut microbiota had recovered to the point where colonization resistance was 
restored. However, administration of a single dose of clindamycin following a six-
week recovery period off cefoperazone rendered all mice susceptible C. difficile 
colonization and disease. These mice all succumbed to CDI by seven days post 
C. difficile challenge and their microbial community once again shifted to a 
predominance of Proteobacteria with an overall decrease in the Firmicutes, 
specifically members of the Lachnospiraceae family. This result suggested that 
although the community seemed to recover enough to prevent C. difficile 
colonization after six weeks off cefoperazone, it did not recover to its initial 
baseline community. 
 Initial examination of the taxonomic community composition at the family 
level suggested that the gut community of mice that had recovered from 
cefoperazone for six weeks was similar to untreated controls. However, further 
examination of the operational taxonomic units (OTUs) on the specie level (or at 
97% similarity) indicated that the recovered community only shared 
approximately 50% of the OTUs that were in the starting baseline community 
(untreated controls) (Figure 2.12), a community which was able to resist C. 
difficile colonization and disease even after pre-treatment with a single dose of 
clindamycin. Antonopoulos and colleagues observed that mice treated with 
cefoperazone had long term alterations in the gut community (1). Similarly our 
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results confirmed this finding. Therefore, cefoperazone treatment was associated 
with long-term alterations in the gut community which resulted in increased 
susceptibility to C. difficile colonization and disease following clindamycin 
treatment. 
  
Figure 2.12  Long-term alteration in gut community after cefoperazone 
treatment. Venn diagram showing the number of shared OTUs between 
untreated mice (n=4) and mice treated with 10 days of cefoperazone followed by 
a 6-week recovery period (n=4). The total number of OTUs in the untreated 
community was 104 and 95 in the cefoperazone recovery community. Only 51 
OTUs were shared between the two groups suggesting that the microbial 
community of cefoperazone treated mice had long-term alterations. 16S rRNA 
gene sequences from each group were placed into OTUs at 97% similarity using 
mothur (54). OTU- operational taxonomic unit. 
The specific microbiota harbored by an individual plays a key role in 
mediating colonization resistance. In our hands, wild-type C57BL/6 mice from our 
breeding colony could not be colonized by C. difficile without antibiotic pre-
treatment. However, Lawley and colleagues have reported that low-level C. 
difficile colonization of C57BL/6 mice could be achieved without antibiotic pre-
treatment (31). These investigators also demonstrated that administration of 
clindamycin to C. difficile-colonized mice would result in a transient increase in 
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the shedding of the organisms which again indicates that disturbances in the 
microbial community structure of the microbiota alters the ecology of C. difficile in 
the GI tract. These results suggest that clinical outcomes following antibiotic pre-
treatment and C. difficile infection may depend on the level of recovery of the 
altered microbial community toward the baseline state.  
 The mechanisms by which the indigenous microbiota can resist 
colonization and limit disease are not clear. Although direct competition between 
organisms within the GI tract is possible (59), it has been recently demonstrated 
that changes in the gut microbial community can indirectly affect colonization 
resistance via differential host responses. For example, decreasing the overall 
bacterial community through the administration of antibiotics can result in 
decreased host production of the antimicrobial peptide RegIIIγ (6). RegIIIγ binds 
the surface-exposed peptidoglycan layer of Gram-positive organisms with high 
affinity in a calcium-independent manner (33). Expression of RegIIIγ appears to 
be driven by the indigenous gut microbiota through host sensing of microbial-
associated molecular patterns, primarily from Gram-negative organisms. RegIIIγ 
has been shown to be important in mediating colonization resistance to 
vancomycin resistant Enterococcus (5). However, in our animals we did not find 
a direct relationship between changes in RegIIIγ expression following antibiotic 
treatment and colonization resistance to C. difficile. 
The development of specific host immune responses against C. difficile 
appears to have an important role in determining the severity of CDI, including 
the development of recurrent disease (29). This observation underscores the 
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exploration of C. difficile vaccines as a novel treatment/ prevention modality (16, 
32, 46, 48). Our current model is characterized by the acute development of 
disease and employs naïve mice, and thus C. difficile-specific adaptive 
responses are not thought to play a role. However, since this model can be 
manipulated such that the disease is not uniformly fatal (unlike the hamster 
model of disease), it remains to be determined if this model will be useful for 
studying adaptive immunity in CDI.  
Recently, Theriot and colleagues (60) demonstrated that the cefoperazone 
model can be manipulated by utilizing less severe strains of C. difficile to produce 
a non-lethal murine CDI model. This model could provide a useful tool to study 
the adaptive immune response in mice infected with C. difficile. There are other 
reports that the five antibiotic and clindamycin model is useful for studying the 
role of innate immune responses in CDI (18, 24). It is important to note that the 
role of immune responses in CDI is likely not independent of that of the 
indigenous microbes. It is clear that the gut microbiota has a key role in 
modulating the development of mucosal immune responses (21, 22). Therefore, 
changes in the gut microbiota, can influence the response to pathogens by 
altering the nature of host immunity (51, 67). 
 Another mechanism by which altered gut microbial communities could 
affect a pathogen is by changing the overall chemical environment of the gut. 
Changes in the community structure of the gut microbiota can dramatically alter 
the concentrations of microbial metabolites (53, 69). When comparing the gut 
microbial communities found in our animals that were clinically well versus those 
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that were succumbing to CDI, the most obvious differences were the dominance 
of Proteobacteria in the ill animals and the return of Firmicutes, specifically 
members of the family Lachnospiraceae in well animals.  These latter organisms 
are notable in that many are able to ferment complex carbohydrates to short-
chain fatty acids (SCFA), which have an important role in maintaining intestinal 
homeostasis (2, 49, 68). With regards to C. difficile, SCFA are able to inhibit the 
growth of the organism and decrease toxin production in vitro (36).  
  In summary, our results demonstrate that the community structure (not 
the absolute level) of the indigenous gut microbiota plays a crucial role in shaping 
the outcome of C. difficile infection. The use of tractable murine models of 
disease should provide insight into the role that the indigenous gut microbiota 
plays in defense against pathogenic microbes. It remains to be seen which of the 
possible interactions between the host, indigenous microbiota and pathogen are 
important in determining the clinical outcome of infection. However, further study 
could lead to novel methods for the treatment and prevention of this increasing 
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Suppression of Clostridium difficile in the Gastrointestinal Tract of Germ-
free Mice Inoculated with a Murine Lachnospiraceae Isolate 
 
3.1 Introduction 
Clostridium difficile is a Gram-positive toxin-producing bacterium first 
described as a commensal organism in the fecal microbiota of healthy newborn 
infants (18). Currently, C. difficile is the most common cause of health care-
associated diarrhea and colitis. C. difficile infection (CDI) is responsible for 
significant morbidity, mortality and increased economic burden in hospitalized 
patients (9, 23). Risk for the development of CDI is associated with the use of 
broad-spectrum antibiotic therapy as well as increasing patient age and 
hospitalization (2).  
 The human gastrointestinal (GI) microbiota protects the host against 
colonization by exogenous pathogenic organisms, a function referred to as 
colonization resistance (17, 40, 42). Administration of broad-spectrum antibiotics 
is theorized to destroy this protective function of the indigenous microbiota, 
allowing C. difficile to proliferate and colonize the GI tract (32, 35, 41). In support 
of this hypothesis, mice or hamsters challenged with C. difficile are not readily 
susceptible to C. difficile colonization or disease (CDI) (5, 45, 47) while antibiotic 
administration will render animals susceptible to infection (3, 5, 12, 20, 30).  
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In previous studies, it was demonstrated that wild-type mice treated with a 
cocktail of five antibiotics and clindamycin prior to C. difficile challenge would 
follow one of two clinical courses. At the appropriate challenge dose mice would 
either develop rapidly lethal CDI or were stably colonized with the development 
of only mild disease (5, 30). We reported that members of the bacterial family 
Lachnospiraceae dominated the gut communities of animals with mild disease. 
Members of the Lachnospiraceae were also the primary component of the GI 
community in untreated mice from our colony. On the other hand the GI 
community of moribund animals had a predominance of Escherichia coli (30). 
Based on this observation, we hypothesize that members of the 
Lachnospiraceae family (but not E. coli) were responsible for at least a portion of 
the natural colonization resistance against C. difficile in the murine GI tract.  
In order to directly examine this hypothesis I isolated Lachnospiraceae 
and E. coli from the cecum of mice and tested their ability to suppress C. difficile 
colonization, toxin production and disease in germ-free mice. Our results indicate 
that Lachnospiracaeae can play an important role in limiting C. difficile 
colonization. Further study could lead to new modes of C. difficile suppression 
and greater insight to the function of these organisms in health and disease.  
 
3.2 Materials and Methods 
3.2.1 Animals and housing 
Wild-type C57BL/6 mice from a breeding colony established using animals 
purchased from Jackson Laboratories were housed with autoclaved food, 
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bedding and water under specific pathogen free conditions. Cage changes were 
performed in a laminar flow hood. Infection studies were performed with 6-8 
week old germ-free Swiss Webster mice from a breeding colony established at 
the University of Michigan germ-free core facility. Mice were housed in sterile 
soft-sided plastic isolators with autoclaved food, bedding and water for the 
duration of the experiments. Each experimental group was housed in a separate 
isolator. All animal protocols used during the conduct of these experiments were 
reviewed and approved by the University Committee on Use and Care of Animals 
of the University of Michigan, Ann Arbor. The protocol was reviewed following 
guidelines for the care and use of laboratory animals set by the Office of 
Laboratory Animal Welfare, United States Department of Health and Human 
Services. 
3.2.2 Development of Lachnospiraceae 16S rRNA-encoding gene primers 
Partial 16S rRNA gene sequences for Lachnospiraceae from our previous study 
(30) were used to generate CLUSTALW multiple sequence alignments. Regions 
of conserved homology from the most common Lachnospiraceae operational 
taxonomic units (OTUs) were identified and used for PCR primer design. These 
conserved regions were compared against 16S rRNA gene sequences of other 
non-Lachnospiraceae bacteria to ensure primer specificity. Primer specificity was 
confirmed by performing PCR amplification on representative 16S rRNA 
sequences of non-Lachnospiraceae clones including E. coli, Pseudomonas, 
Porphyrmonodaceae, Bacteroides, Verrucomicrobia, Lactobacillus, 
Clostridiaceae, Staphylococcus, Ruminococcaceae and Peptococcaceae strains. 
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The final Lachnospiraceae-specific forward primer (LachnoF 5’- ACC GCA TAA 
GCG CAC AGC-3’) was used with the broad-range reverse bacterial primer 
1492R (1492R 5’-GGT TAC CTT GTT ACG ACT T-3’) for PCR with the following 
cycling conditions; initial denaturation at 95°C for 2 min followed by 30 cycles of 
denaturation at 95°C for 30 sec, annealing at 56°C for 45 sec and extension at 
72°C for 90 sec. A final extension at 72°C for 10 min was performed. PCR was 
performed with 20 pmol of each primer (LachnoF, 1492R), 8 mM dNTP master 
mix (Promega-U1511), 1 unit GoTaq DNA polymerase (Promega- M3005), PCR 
buffer (Promega- M3005) and water in a total of 25 µl per reaction. 
3.2.3 Bacterial isolation from specific-pathogen free mice  
The plate wash PCR technique (36) was adapted for the isolation of murine 
Lachnospiraceae strains. Ceca from wild-type C57BL/6 mice were removed in a 
sterile manner and immediately transferred to an anaerobic chamber (Coy 
Industries). Anaerobically equilibrated 1x phosphate-buffered saline (PBS) was 
added to the cecum and the organ was opened with a sterile scalpel to release 
the cecal contents. Serial dilutions of this cecal suspension were plated in 
triplicate on various types of culture media including trypticase peptone (BD, cat# 
211043) with 5% blood (blood agar), chocolate agar (consisting of 5% lysed 
blood) with trypticase peptone base, reinforced clostridial agar (BD cat# 218081), 
modified peptone yeast glucose agar (ATCC medium #1237), routine growth 
media (RGM) (8) and brain heart infusion agar (BD, cat# 211065) with 0.1% 
cysteine (Sigma-Aldrich, cat# C7352) added (BHIS) in combination with 
aztreonam (Sigma-Aldrich, cat# A6848) and gentamicin (Sigma-Aldrich, cat# 
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G1914) to determine which media would provide the greatest enrichment of 
Lachnospiraceae. The surface of one agar plate was scraped to remove all 
bacterial colonies and bacterial DNA was extracted using an automated system 
(Roche MagNA Pure, cat# 03730964001). Enrichment for Lachnospiraceae was 
determined by performance of the Lachnospiraceae specific 16S rRNA gene 
PCR and the amplification of the expected 1320 base pair band. The greatest 
enrichment for Lachnospiraceae was obtained using BHIS plates supplemented 
with 2 mg/L gentamicin and 1 mg/L aztreonam (BHIS gen/az). Subsequently, 
individual colonies from the remaining BHIS gen/az plates in the anaerobic 
chamber were inoculated into 250 µl of BHIS gen/az broth in a sterile 96-well 
plate then incubated anaerobically at 37°C and growth was monitored. PCR 
using 1 µl of bacterial culture was used to identify putative Lachnospiraceae. 
Genomic bacterial DNA was extracted using an automated system (Roche 
MagNA Pure) from cultures of putative Lachnospiraceae isolates. Sequencing of 
full-length 16S rRNA gene sequences was obtained using the following primers: 
8F (5’-AGA GTT TGA TCC TGG CTC AG-3’), 515F (5’- GTG CCA GCM GCC 
GCG GTA-3’), E939R (5’- CTT GTG CGG GCC CCC GTC AAT TC-3’) and 
1492R (5’-GGT TAC CTT GTT ACG ACT T-3’). DNA sequencing was performed 
by the DNA Sequencing Core facilities at the University of Michigan. Isolation of 
Escherichia coli was performed by selectively plating murine cecal contents on 
MacConkey agar anaerobically at 37°C. The identity of putative E. coli isolates 
was confirmed by sequencing the 16S rRNA-encoding gene amplicon. 16S rRNA 
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gene sequence analysis and taxonomic classification was performed using the 
RDP Bayesian classifier implemented in mothur (33). 
3.2.4 Clostridium difficile strains and growth conditions  
C. difficile spores were prepared from strains VPI 10463 (ATCC 43255) and 630 
(ATCC BAA-1382) as follows. C. difficile was cultured overnight anaerobically at 
37ºC in brain heart infusion broth with 0.1% cysteine (BHIS). On the following 
day, 100 µl of these cultures were spread onto BHIS plates (four plates per 
strain) and the plates incubated for seven days anaerobically at 37ºC. The plates 
were removed from the anaerobic chamber and exposed to ambient oxygen for 
24 hr at room temperature to kill vegetative cells. Plates were flooded with 15 ml 
cold water and bacteria were removed by scraping with a sterile loop. Bacterial 
suspensions were centrifuged and washed in cold water at least three times. 
Spore stocks were stored at 4ºC in sterile water. The presence of spores was 
confirmed using phase contrast microscopy and stocks were enumerated by 
plating for viable colony forming units on TCCFA (Taurocholate cycloserine 
cefoxitin fructose agar). C. difficile spores were heat treated for 20 min at 65°C to 
ensure that all spores were viable prior to gavaging animals with 100 µl of a 
specific dose of the spore suspension (39). Culture plates were incubated in an 
anaerobic chamber (Coy Industries) at 37°C for 24 hr.  
3.2.5 Germ-free mouse infection studies  
Six to 8 week-old germ-free Swiss Webster mice were divided into groups of 3 - 
9 animals. Each treatment group was housed in separate sterile isolators. 
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Initially, mice were challenged via oral gavage with varying spore doses of two C. 
difficile strains VPI 10463 or strain 630 to determine the appropriate dose of 
spores to use for the remaining experiments. For C. difficile VPI 10463, mice 
were challenged with 3.8 x 101, 3 x 102, 3.3 x 103 and 1 x 105 spores while for C. 
difficile strain 630 mice were challenged with 1 x 101, 1 x 102, 1 x 103 and 1 x 104 
spores (Figure 3.1) with each group consisting of 3 to 5 mice. Based on these 
experiments 100 spores were used as the challenge dose for all experiments. 
Mice were pre-colonized via oral gavage with 1 x 108 CFU of either Escherichia 
coli or Lachnospiraceae D4 for four days. As a control, mice were also orally 
gavaged with single dose of cecal content homogenate obtained from a wild-type 
mouse for four days. Each treatment group consisted of 5 to 9 animals. Mice 
were then challenged by oral gavage with 100 spores of C. difficile (VPI 10463 or 
strain 630) and monitored daily for signs of disease such as diarrhea, hunched 
posture and weight loss. Control groups consisted of animals colonized with only 
C. difficile (n=11 and n=15 for strain 630 and VPI 10463 respectively), E. coli 
(n=4), Lachnospiraceae D4 (n=4), cecal content homogenate from wild-type mice 
(n=3) or no bacteria (n=5) (Figure 3.1). Bacterial colonization was monitored daily 
by anaerobically culturing fecal pellets and cecal contents at necropsy at 37°C for 
24 hr. E. coli colonization was monitored by culture on MacConkey agar while the 
levels of Lachnospiraceae D4 were monitored by culture on BHIS gen/az. The 
colonization status of C. difficile challenged animals was monitored by anaerobic 
culture on TCCFA.  
 







Figure 3.1  Schematic for examining the effect of Lachnospiraceae D4 and E. 
coli on C. difficile colonization in germ-free mice. Mice were infected with titrating 
doses of C. difficile 630 (10, 102, 103, 104) spores (n=3 per dose) or C. difficile 
VPI 10463 (38, 3x102, 3.3x103, 1x105) spores (n=4 per dose) and monitored for 
colonization. Animals were colonized with cecal contents from a wild-type mouse 
for 4 days prior to C. difficile VPI 10463 challenge (n=5). Additionally, mice were 
either pre-colonized with E. coli then challenged with C. difficile 630 (n=9) or C. 
difficile VPI 10463 (n=7) spores or pre-colonized with Lachnospiraceae D4 then 
challenged with C. difficile 630 (n=8) or C. difficile VPI 10463 (n=14) spores. Mice 
mono-colonized with C. difficile 630 (n=11) or C. difficile VPI 10463 (n=15) were 
done as controls. Other groups of mice were colonized with either E. coli (n=4) or 
Lachnospiraceae D4 (n=4) for 4 days and harvested. The cecum and colon from 
each animal was harvested for bacterial and cytotoxin quantification.  
 
3.2.6 Necropsy and histological procedures 
 Mice were euthanized by CO2 asphyxiation. Approximately 5 mm of the proximal 
colon, terminal ileum tissue, and luminal contents were collected for each animal, 
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colon tissue were placed intact into histology tissue cassettes and stored in 10% 
buffered formalin for 24 hr then transferred to 70% ethyl alcohol. Tissue 
cassettes were then processed, paraffin embedded and 5 µm sections prepared. 
Haematoxylin and eosin stained slides were prepared for histologic examination 
(McClinchey Histology Lab Inc. Stockbridge, MI.)  
3.2.7 Histopathologic examination 
Histological changes were coded, randomized, and scored in a blinded manner 
by a board-certified veterinary pathologist. A scoring system was adapted from a 
previously published method (5, 22). Edema, neutrophilic inflammation and 
epithelial damage in colon and cecum were scored from 0-4 according to the 
following defined criteria: Edema scores – 0, no edema; 1, mild edema with 
minimal (<2x) multifocal submucosal expansion; 2, moderate edema with 
moderate (2-3x) multifocal sub-mucosal expansion; 3, severe edema with severe 
(>3x) multifocal sub-mucosal expansion; and 4, same as score 3 with diffuse 
sub-mucosal expansion. Neutrophilic inflammation scores were graded as 
follows: 0, no inflammation; 1, minimal multifocal neutrophilic inflammation 
(marginating or perivascular neutrophils in submucosa, minimal intraepithelial 
and proprial neutrophils); 2, moderate multifocal neutrophilic inflammation 
(perivascular and interstitial neutrophils in submucosa, mild to moderate 
intraepithelial and proprial neutrophils); 3, severe multifocal to coalescing 
neutrophilic inflammation (perivascular and increased interstitial neutrophils in 
submucosa +/- extension to muscular wall, moderate intraepithelial neutrophils); 
and 4 same as score 3 with abscesses. Epithelial damage was scored as follows: 
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0, no epithelial changes; 1, minimal multifocal superficial epithelial damage 
(vacuolation, apoptotic figures, villus tip attenuation/necrosis); 2, moderate 
multifocal superficial epithelial damage (vacuolation, apoptotic figures, villus tip 
attenuation/necrosis); 3, severe multifocal epithelial damage (same as above) +/- 
pseudomembrane (intraluminal neutrophils, sloughed epithelium in a fibrinous 
matrix); and 4, same as score 3 with significant pseudomembrane or epithelial 
ulceration (focal complete loss of epithelium).  
3.2.8 C. difficile cytotoxin assay  
Quantification of C. difficile toxin present in luminal contents was performed using 
a method adapted from Corthier et al. (7). Green African monkey kidney 
epithelial cells (Vero) (provided by M. Imperiale, University of Michigan) were 
grown to confluency in DMEM (GIBCO Laboratories, cat# 11965) containing 10% 
heat inactivated fetal bovine serum (GIBCO Laboratories, cat# 16140) and 1% 
Penicillin streptomycin solution (GIBCO Laboratories, cat# 15140). The cells 
were trypsinized using 0.25% trypsin (GIBCO Laboratories, cat# 25200) and 
washed with 1 volume of DMEM medium. Cells were diluted in DMEM medium 
and approximately 1x105 cells were distributed per well in a 96-well flat bottom 
microtiter plate (Corning) and incubated at 37°C for 18-24 hours.100 mg of 
luminal contents were weighed and 500 µl of 1x PBS was added to make a 
suspension. Samples were mixed and then particulate material removed by 
centrifugation at 9000 x g for 5 min and then the supernatant was filtered through 
a 0.2 µm membrane. Each sample was titrated in ten-fold dilutions within the 
wells to a maximum dilution of 10-12 and each well had a corresponding control to 
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which both neutralizing C. sordelli antitoxin (TechLabs, cat# T5000) and sample 
were added. After an overnight incubation at 37°C, plates were fixed with 10% 
buffered formalin for 2 hours then stained with geimsa (50 µl per well) for 15 min 
followed by a wash with 1x PBS. Wells with approximately 100% round cells 
were easily recognized under 200x magnification. The cytotoxic titer was defined 
as the reciprocal of the highest dilution that rounds 100% of Vero cells per gram 
of sample.  
3.2.9 Short-chain fatty acid (SCFA) measurement  
In vivo SCFA measurement was performed as follows: groups of four 6-8 week 
old Swiss Webster germ-free mice were colonized with either 108 CFU of E. coli 
or Lachnospiraceae D4 for four days. Additionally, a third group remained germ-
free as a control. All mice were necropsied, cecal contents were removed, 
weighed, flash frozen and stored at -80°C. Samples were sent to the Michigan 
Metabolomics and Obesity Center at the University of Michigan for SCFAs 
measurement by gas chromatography-mass spectrometry (GC-MS). GC (Agilent 
6890) separation was performed using a ZB-Wax plus column (0.25 µm x 0.25 
mm x 30 m) and a quadruple mass spectrometer (Agilent, 5973 inert MSD) was 
used to identify and quantitate SCFAs using Agilent Chemstation software. 
3.2.10  Fluorescent in situ hybridization (FISH) 
Representative 5 µm paraffin embedded cecal and colon sections from mice 
colonized with C. difficile only, E. coli and C. difficile or Lachnospiraceae D4 and 
C. difficile were prepared on slides. Each tissue section was de-paraffinized by 
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performing two 5-minute washes in xylene, followed by two 5-minute washes in 
100% ethanol then each section was rinsed in sterile water. Hybridization buffer 
(2 ml per slide) was made using the following: 360 µl 5M NaCl, 40 µl 1M Tris-HCl 
pH 7.2, 700 µl formamide, 2 µl 10% SDS and 900 µl sterile water. Fluorescently 
labeled probes CY3-Eub338 (general bacteria probe) and CY5-Cd198 (C. difficile 
specific probe) each at 5 ng/ µl was added to 100 µl hybridization buffer then 
applied to each section. The slide was then placed in a hybridization chamber 
with the remaining buffer for 2 hours at 46ºC. A wash buffer pre- warmed to 48ºC 
was made as follows: 700 µl 5M NaCl, 1 ml 1M Tris-HCl pH 7.2, 500 µl 0.5M 
EDTA pH 8, 50 µl 10% SDS and water added to make 50 ml total. Each slide 
was removed from the hybridization chamber and placed in 25 ml of pre-warmed 
wash buffer and incubated at 48ºC for 40 minutes. After wash, each slide was 
mounted using VectaShield mounting medium (Vector Laboratories Inc., cat# H-
1000) to protect from photobleaching and then images were captured using a 
fluorescent microscope. Images labeled with CY3-Eub338 were false colored red 
while images labeled with CY5-Cd198 were false colored green. Background 
fluorescence for each image was captured and false colored magenta. Images 
were merged using Adobe Photoshop CS5 version 12.0. 
3.2.11 Statistical analysis  
Statistical analyses were performed using Prism 5 for Mac OS X GraphPad 
Software. The nonparametric Krustal Wallis test was used to determine 
significance for all treatment groups while Student’s t test was used for individual 
comparisons. Statistical significance was set at a P value of <0.05. 
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3.3 Results 
3.3.1 Isolation and characterization of murine Lachnospiraceae and E. coli 
A strain of E. coli was isolated from the murine gut by selectively plating murine 
cecal contents on MacConkey agar. The identification of potential E. coli cultivars 
was confirmed by 16S rRNA gene sequence analysis. To isolate 
Lachnospiraceae, 16S-targeted rRNA-encoding gene primers were designed 
based on the partial 16S rRNA gene sequences from our previous study (30), to 
guide cultivation efforts via the plate wash PCR technique (36). The greatest 
enrichment for Lachnospiraceae was achieved by selectively plating murine 
cecal contents on brain heart infusion agar supplemented with 0.1% cysteine, 2 
mg/L gentamicin and 1 mg/L aztreonam (BHIS gen/az) under anaerobic 
conditions. A total of 14 Lachnospiraceae isolates based on 16S rRNA-encoding 
gene sequence were confirmed (Figure 3.2).  We determined the phylogenetic 
relationship of these isolates to the most abundant phylotypes (clostridial 
clusters) of the low molecular % G+C Gram-positive bacteria in the Fimicutes 
phylum (Figure 3.2). All 14 Lachnospiraceae isolates were members of the 
clostridial cluster XIVa (10). 
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Figure 3.2  Phylogenetic tree showing clostridial clusters of low molecular % 
G+C Gram-positive bacteria based on 16S rRNA sequence. The tree was 
constructed using the neighbor joining method with the murine E. coli isolate 
used as the out-group. Newly isolated murine Lachnospiraceae strains are 
shown in bold face. Accession numbers for sequences are given in brackets. 
Boot-strap values greater than 95 (per 500 replicates) are shown at branch 
points. The scale bar represents genetic distance and clostridial clusters are 
indicated by Roman numerals. 
 
  Lachnospiraceae  isolate  F1  
  Lachnospiraceae  isolate  H6a  
  Lachnospiraceae  isolate  F6  
  Lachnospiraceae  isolate  H10b
  Lachnospiraceae  isolate  H10a  
  Lachnospiraceae  isolate  E7  
  Lachnospiraceae  isolate  H6b  
  Lachnospiraceae  isolate  D1
    Lachnospiraceae  isolate  C6  
  Lachnospiraceae  isolate  F2  
  Lachnospiraceae  isolate  E101
  Clostridium  hathewayi  DSM  13479  (AJ311620)
  Clostridium  saccharolyticum  DSM  2544  (Y18185)
  Clostridium  clostridioforme  strain  136069/2010  (HM008264)
  Lachnospiraceae  isolate  D4
  Clostridium  bolteae  strain  16351  (NR_025567)  
  Clostridium  asparagiforme  DSM  15981  (AJ582080)
  Blautia  luti  DSM  14534  (AJ133124)
    Ruminococcus  obeum  ATCC  29174  (X85101)
  Blautia  producta  ATCC  27340  (X94966)
  Dorea  longicatena  DSM  13814  (AJ132842)
  Ruminococcus  gnavus  ATCC  29149  (X94967)
  Clostridium  nexile  DSM  1787  (X73443)
  Coprococcus  comes  ATCC  27758  (EF031542)
  Rosburia  inulinivorans  DSM  16841  (AJ270473)
  Eubacterium  ramulus  ATCC  29099  (L34623)
  Butyrivibrio  fibrisolvens  16.4  (AJ250365)
    Eubacterium  rectale  ATCC  33656  (L34627)
  Rosburia  faecis  DSM  16840  (AY305310)
  Rosburia  hominis  DSM  16839  (AJ270482)
  Rosburia  intestinalis  DSM  14610  (AJ312385)
  Lachnospiraceae  isolate  G11
  Lachnospiraceae  isolate  G3
  Anaerostipes  caccae  DSM  14662  (AJ270487)
  Eubacterium  eligens  ATCC  27750  (L34420)
  Eubacterium  hallli  ATCC  27751  (L34621)
  Coprococcus  eutactus  ATCC  27759  (EF031543)
  Coprococcus  sp.  L2-­50  (AJ270491)
  Eubacterium  angustum  ATCC  43737  (L34612)
  Clostridium  formiaceticum  DSM  92  (X77836)
  Clostridium  aminobutyricum  DSM  2634  (X76161)
  Clostridium  difficile  DSM  11209  (X73450)
  Clostridium  bartlettii  CCUG  48940  (AY438672)
  Clostridium  glycolicum  DSM  1288  (X76750)
  Clostridium  lituseburense  ATCC  25759  (M59107)
  Clostridium  bifermentans  ATCC  638  (X75906)
  Eubacterium  siraeum  ARCC  29066  (L34625)
  Anaerofilum  pentosovorans  DSM  7168  (X97852)
  Faecalibacterium  prausnitzii  DSM  17677  (AJ270469)
  Ruminococcus  flavefaciens  ATCC  19208  (X85097)
  Ruminococcus  callidus  ATCC  27760  (X85100)
  Ruminococcus  albus  ATCC  27210  (X85098)
  Anaerotruncus  colihominis  CCUG  45055  (AJ315980)
  Ruminococcus  bromii  ATCC  27255  (X85099)
  Clostridium  leptum  DSM  753  (AJ305238)
  Eubacterium  barkeri  ATCC  25849  (M23927)
  Eubacterium  limosum  ATCC  8486  (M59120)
  Eubacterium  callanderii  DSM  3662  (X96961)
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These Lachnospiraceae isolates were further characterized based on 
growth on BHIS gen/az plates and BHIS gen/az broth. Of the 14 
Lachnospiraceae isolates, 13 took 3-4 days to grow on solid media and grew 
poorly in broth culture. The remaining isolate (referred to as D4) was most 
closely related to Clostridium clostridioforme based on 16S rRNA gene sequence 
(Figure 3.2). Lachnospiraceae isolate D4 grew very well on solid media and in 
broth culture which allowed us to test its ability to inhibit C. difficile growth and 
toxin production in germ-free mice. 
3.3.2 Colonization of germ-free mice with Lachnospiraceae D4 interferes 
with subsequent C. difficile colonization  
We recently demonstrated that cefoperazone-treated mice were readily colonized 
with C. difficile strain 630 but did not exhibit signs of clinically severe CDI such as 
weight loss, diarrhea or hunched posture (39). As such, infection of 
cefoperazone-treated mice with C. difficile 630 permits the examination of the 
effect of Lachnospiraceae D4 and E. coli on C. difficile colonization and cytotoxin 
production in a non-lethal infection model. We initially challenged germ-free mice 
with varying doses of C. difficile 630 spores ranging from 101 to 104 (Figure 3.1) 
to determine if the lack of lethality observed in antibiotic-treated animals would 
extend to mono-colonization with this strain. C. difficile colonization levels were 
monitored daily by culture of fecal pellets and culture of cecal contents at 
necropsy.  
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Figure 3.3  C. difficile infection in germ-free mice. Kaplan-Meier survival plot for 
mice infected with titrating doses of (A) C. difficile 630 spores (1 x 101, 1 x 102, 1 
x 103, 1 x 104) and (B) C. difficile VPI 10463 spores (3.8 x 101, 3 x 102, 3.3 x 103, 
1 x 105). Quantification of C. difficile was determined by culturing cecal contents 
at the time of necropsy: (C) at day 6 from mice infected with C. difficile 630 for 
each challenge dose (n=3) or (D) at days 1 or 2 for mice infected with C. difficile 
VPI 10463 for each challenge dose (n=4). Vero cell tissue culture was used to 
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mice in (C and D) infected with (E) C. difficile 630 or (F) C. difficile VPI 10463 for 
each challenge dose. Points on each graph represent individual animals. Error 
bars represent standard deviation.  
 
Levels of C. difficile cytotoxin were measured using a Vero cell assay. As with 
conventional mice, germ-free mice challenged with C. difficile 630 did not exhibit 
clinical signs of CDI and survived the infection (Figure 3.3A). Mono-colonized 
animals had high levels of C. difficile colonization (>109 CFU/ gram) (Figure 
3.3C). Similar results were seen regardless of the infectious dose administered. 
Subsequently, we employed an infectious dose of 100 C. difficile 630 spores for 
the following experiments. 
         Germ-free mice received 108 CFU of either Lachnospiraceae D4 or E. coli 
via oral gavage. Mice challenged with either bacteria were readily colonized but 
the levels of Lachnospiraceae D4 in the feces of colonized animals was 
approximately 2 logs lower than that reached by E. coli in mono-colonized mice 
(Figure 3.4). Four days after pre-colonization with either Lachnospiraceae D4 or 
E. coli animals were challenged with 100 spores of C. difficile strain 630. All mice 
challenged with C. difficile were successfully colonized and this colonization did 
not alter the level of fecal Lachnospiraceae or E. coli colonization (Figure 3.4). 












Figure 3.4  Intestinal cecal colonization levels by E. coli and Lachnospiraceae 
D4 after C. difficile challenge. Mice were pre-colonized with either E. coli or 
Lachnospiraceae D4 for 4 days then infected with C. difficile 630. Both E. coli 
and Lachnospiraceae D4 levels were measured daily in feces by culture. For 
each day of the experiment colonization levels for E. coli reached 1012 CFU while 
Lachnospiraceae D4 reached 109-1010 CFU. P value was calculated using 
student’s t test and was significant (p = <0.0001) between the two groups. Error 
bars represent standard deviation. CFU- colony forming units. Lachno D4- 
Lachnospiraceae D4 
 
In mice pre-colonized with E. coli prior to C. difficile challenge, there was 
no difference in the cecal levels of colonization by C. difficile compared to mice 
monocolonized with C. difficile strain 630 (Figure 3.5A). On the other hand, mice 
pre-colonized with Lachnospiraceae D4 prior to C. difficile challenge had a 
significant decrease in the levels C. difficile colonization (>1.5 log) (Figure 3.5A) 
and a corresponding decrease in the amount of C. difficile cytotoxin in the cecal 
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Figure 3.5 Decreased levels of C. difficile 630 and cytotoxin in Lachnospiraceae 
D4 pre-colonized mice. (A) Quantification of C. difficile was determined by 
culturing cecal contents at the time of necropsy (day 6) from mice infected with 
C. difficile only (n=11) or pre-colonized with either E. coli (n=9) or 
Lachnospiraceae D4 (n=8) then infected with C. difficile.  Each point represents 
the C. difficile level from an individual animal. Mice pre-colonized with 
Lachnospiraceae D4 had significantly decreased levels of C. difficile compared to 
C. difficile controls or E. coli pre-colonized mice. Error bars represent standard 
deviation. Comparisons between groups were performed using the non-
parametric Krustal Wallis test. (B) Vero cell tissue culture was used to determine 
the log10 reciprocal cytotoxin dilution per gram of cecal contents from mice in (A) 
infected with C. difficile only or pre-colonized with either E. coli or 
Lachnospiraceae D4 then infected with C. difficile.  Error bars represent standard 
deviation. Comparisons between groups were performed using the non-
parametric Krustal Wallis test. C.d - C. difficile, Lachno D4- Lachnospiraceae D4. 
CFU- colony forming units 
 
3.3.3 Colonization of germ-free mice with Lachnospiraceae isolate D4 
decreases subsequent disease severity after challenge with C. difficile 
strain VPI 10463  
C. difficile VPI 10463 has been shown to cause acute, severe and often 
lethal form of CDI in antibiotic-treated wild-type and germ-free mice (21, 30, 39). 
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(Figure 3.3) all developed clinically severe CDI with diarrhea, hunched posture 
and significant (>20% from baseline) weight loss. All mice regardless of 
challenge dose were either dead or moribund by 1-2 days post challenge (Figure 
3.3B). High levels of C. difficile (>109 CFU/ gram) (Figure 3.3D) and cytotoxin 
were detected in cecal contents at the time of necropsy when compared to 
animals monocolonized with C. difficile 630 (Figure 3.3E, 3.3F). Similar to 
animals monocolonized with C. difficile VPI 10463, mice pre-colonized with E. 
coli prior to C. difficile challenge lost > 20% of baseline body weight by 2 days 
post infection (Figure 3.6) and had high levels of C. difficile colonization and 







Figure 3.6  Weight loss in C. difficile infected mice. Weight loss curves for C. 
difficile infected mice (n=15), mice pre-colonized with Lachnospiraceae D4 and 
infected with C. difficile (n=14) and mice pre-colonized with E. coli and infected 
with C. difficile (n=7). Lachnospiraceae D4 pre-colonized mice lost less weight 
than C. difficile or E. coli pre-colonized mice. Weight loss percentage is based on 
the starting weight on day 0. Error bars represent the standard deviation of the 
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Conversely, mice pre-colonized with Lachnospiraceae D4 demonstrated 
significantly less clinically severe disease following challenge with C. difficile VPI 
10463. Of a total of 14 mice, 3 were moribund and lost significant weight while 
the remaining 11 had minimal weight loss and were clinical well 2 days post 
infection (Figure 3.6). The 11 surviving mice also had lower levels of C. difficile 
colonization and measureable cytotoxin (Figure 3.7) compared to the moribund 
mice and mice challenged C. difficile alone or following prior colonization with E. 
coli.   
 
Figure 3.7  Decreased C. difficile VPI 10643 colonization and cytotoxin levels in 
Lachnospiraceae D4 pre-colonized mice. (A) Quantification of C. difficile was 
determined by culturing cecal contents at the time of necropsy (day 2) from mice 
infected with C. difficile only (n=15) or pre-colonized with E. coli (n=7) or 
Lachnospiraceae D4 (n=14) then infected with C. difficile. The levels of C. difficile 
colonization was decreased in Lachnospiraceae D4 pre-colonized compared to 
C. difficile controls or E. coli pre-colonized mice. Each point represents the C. 
difficile level from an individual animal. The open points represent animals that 
had improved CDI signs and did not lose significant weight while the closed 
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necropsy. (B) Vero cell tissue culture was used to determine the log10 reciprocal 
cytotoxin dilution per gram of cecal contents from mice in (A) infected with C. 
difficile only or pre-colonized with E. coli or Lachnospiraceae D4 then infected 
with C. difficile.  Error bars represent standard deviation. Comparisons between 
groups were performed using the non-parametric Krustal Wallis test. C.d - C. 
difficile, Lachno D4- Lachnospiraceae D4.  
Germ-free mice pre-colonized with Lachnospiraceae D4 prior to challenge 
with C. difficile VPI 10463 had significantly less colonic inflammation and 
submucosal edema than either C. difficile infected controls or animals pre-
colonized with E. coli before C. difficile challenge (Figure 3.8E, 3.8F). Mice that 
were maintained germ-free and mice mono-associated with either 
Lachnospiraceae D4 or E. coli had no histologic alterations (data not shown).  In 
addition to the differences in the colon, there was also significantly less mucosal 
epithelial damage in the cecum of mice pre-colonized with Lachnospiraceae D4 
compared to E. coli pre-colonized and C. difficile control mice (data not shown). 
Representative histological alterations within the C. difficile VPI 10463 
challenged groups are shown in Figure 3.8. Alterations consisted predominantly 
of edema within the submucosa and the mucosal lamina propria. There was also 
neutrophilic inflammation perivascularly and interstitially within the submucosa 
and multifocally within the mucosa (Figure 3.8). Epithelial damage was not 
prominent but consisted of vacuolar degeneration and increased loss of apical tip 
enterocytes.  
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Figure 3.8  Germ-free animals pre-colonized with Lachnospiraceae D4 have 
improved colonic histopathology after C. difficile challenge. (A) Colon of a germ- 
free mouse. HE. Original magnification x100. (B) Colon of a C. difficile infected 
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mouse showing severe edema in the submucosa and mucosal lamina propria 
(arrow) accompanied by neutrophilic inflammation (arrowheads). HE. Original 
magnification x100. (C) Colon from a mouse pre-colonized with E. coli and 
infected with C. difficile showing submucosal edema (arrow) and neutrophilic 
inflammation (arrowheads) similar to a C. difficile infected mouse. HE. Original 
magnification x100. (D) Colon of a mouse pre-colonized with Lachnospiraceae 
D4 and infected with C. difficile showing moderate neutrophilic mucosal 
inflammation (arrowheads) but decreased submucosal edema (arrow) in 
comparison to C. difficile only and E. coli pre-colonized C. difficile infected mice. 
HE. Original magnification x100. Bar represent 100 µm. (E) Categorical scores of 
neutrophilic inflammation and (F) edema in C. difficile infected controls, C. 
difficile infected E. coli pre-colonized mice and C. difficile infected 
Lachnospiraceae D4 pre-colonized mice. Comparisons between groups were 
performed using the non-parametric Krustal Wallis test. C.d- C. difficile, Lachno 
D4- Lachnospiraceae D4 
 
3.3.4 In vivo association of C. difficile, E. coli and Lachnospiraceae D4 in 
the colon  
Thus far, I have demonstrated that Lachnospiraceae D4 decreases the level of 
C. difficile colonization in mice. Next I wanted to determine whether 
Lachnospiraceae D4 occupied a specific physical niche within the colon that 
affected C. difficile colonization. Therefore, I performed FISH on colonic tissue 
from mice colonized with both C. difficile and E. coli or Lachnospiraceae D4 to 
visualize the location of C. difficile, E. coli and Lachnospiraceae D4 and to 
determine whether any interactions with the gut epithelium were occurring 
between these organisms. C. difficile control mice demonstrated the presence of 
C. difficile primarily in the lumen of the colon (Fig. 3.9A, 3.9B). Mice pre-
colonized with E. coli and infected with C. difficile demonstrated the presence of 
both E. coli and C. difficile localized to the colonic lumen. Numerous E. coli and 
C. difficile organisms were also observed visually in the colonic section examined 
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further confirming the inability of E. coli to limit C. difficile colonization (Fig. 3.9C, 
3.9D). Mice colonized with both Lachnospiraceae D4 and C. difficile also 
demonstrated Lachnospiraceae D4 localization to the lumen. However, only few 
C. difficile cells were observed in the sample (Fig. 3.9E, 3.9F) further confirming 
the ability of Lachnospiraceae D4 to decrease the levels of C. difficile 
colonization. Based on these results no specific interaction with the gut 
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Figure 3.9  Examination of C. difficile infected colonic tissue sections by 
fluorescence in situ hybridization. Tissue sections were dual labeled with two 
fluorescence-labeled oligonucleotide probes, one specific for C. difficile and the 
other general for all bacteria. C. difficile appears orange/ yellow while E. coli and 
Lachnospiraceae D4 are red in color. Colon sections of: (A) C. difficile infected 
mice demonstrating the presence of C. difficile primary in the lumen and (B) 
central lumen, (C) mice pre-colonized with E. coli and infected with C. difficile 
demonstrated the presence of both organisms primarily in the lumen with high 
numbers of C. difficile present and (D) central lumen. (E and F) Colonic section 
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from a mouse pre-colonized with Lachnospiraceae D4 and infected with C. 
difficile. Lachnospiraceae D4 was predominant in the lumen with only few C. 
difficile present and (F) central lumen. Arrows represent position of intestinal 
epithelial mucosa. Original magnifications of all images are x1000. 
 
3.3.5 Prevention of C. difficile colonization the GI tract of germ-free mice 
inoculated with cecal contents from wild-type mice 
 Previous results indicate that Lachnospiraceae strain D4 partially restores 
colonization resistance against C. difficile in germ free mice. As a control, I tested 
whether the full complement of cecal microbiota from wild-type mice could 
completely restore colonization resistance in germ free mice. Germ-free mice 
received cecal contents obtained from a wild-type mouse via oral gavage. Four 
days later, these mice were challenged with 100 C. difficile VPI 10463 spores 
(Figure 3.1). Unlike C. difficile mono-associated control mice, mice that were 
colonized with the cecal content homogenate prior to C. difficile challenge did not 
exhibit signs of clinical CDI such as weight loss, diarrhea and hunched posture. 
No detectable C. difficile was present in feces at one-day post challenge or in the 
cecal contents at two days post challenge or at the time of necropsy (data not 
shown).  
3.4 Discussion 
The indigenous GI microbiota plays a fundamental role in colonization 
resistance against C. difficile (43). However, the specific components of the gut 
microbiota that are important in mediating colonization resistance are not well 
defined. In this study we demonstrate that a single component of the murine gut 
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microbiota, a member of the family Lachnospiraceae, is able to partially restore 
colonization resistance against C. difficile in germ-free mice.  
Until now no study has examined the ability of Lachnospiraceae 
organisms to contribute to colonization resistance against C. difficile or other 
pathogens. We recently reported that antibiotic treated mice with clinically severe 
CDI were predominated with E. coli while mice with mild CDI were predominated 
with Lachnospiraceae. Likewise, other studies have associated the microbial gut 
community of patients with inflammatory bowel disease (IBD) to have an 
increased prevalence of E. coli and decreased prevalence of Lachnospiraceae 
(15, 24, 25). Furthermore, patients with IBD are at a higher risk for developing 
CDI (14, 28). These findings prompted us to isolate and investigate the relative 
roles of Lachnospiraceae and E. coli in mediating colonization resistance against 
C. difficile 
The Lachnospiraceae family is made up of many different genera 
including Butyrivibrio, Lachnospira, Rosburia, Coprococcus, Blautia, 
Robinsoniella only to name a few. Members within this family are usually Gram-
positive, though some may appear Gram-negative due to the presence of a very 
thin peptidoglycan later in their bacterial cell wall (19). These organisms are strict 
obligate anaerobes and the nutritional requirement for growth of many of these 
organisms remains largely unknown. As a result only few members within this 
family have been cultured and studied. The Lachnospiraceae are 
phylogenetically placed within the clostridial cluster XIVa of the Clostridium 
subphylum based on 16S rRNA gene sequence (6, 8). Clostridial cluster XIVa is 
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one of the three main clostridial clusters of the low molecular % G+C Gram-
positive bacteria that make up approximately 25% of the total bacterial species 
found in the human colon (10). Since many gut bacteria are adapted to an 
environment of low partial oxygen pressures they may lack electron transport 
chains usually present in facultative anaerobic bacteria to regenerate NADH2 and 
therefore may not gain energy by electron transport level phosphorylation (10). 
As a result, the formation of acidic fermentation products due to the regeneration 
of NAD+ occurs resulting in many Lachnospiraceae members being capable of 
producing large amounts of SCFAs such as acetate, propionate and butyrate. 
These SCFAs serve important roles in maintaining the overall health of the gut 
epithelium and aids in preventing mucosal inflammation (8, 24, 29, 48).  
Our murine Lachnospiraceae isolates were members of the clostridial 
cluster XIVa (3.1). Lachnospiraceae organisms found in both humans and mice 
can have highly similar 16S rRNA gene sequences. In our study the murine 
Lachnospiraceae isolate D4 was phylogenetically similar to Clostridium 
clostridioforme, a Lachnospiraceae organism found in humans (Figure 3.1) (13). 
This organism is present as part of the indigenous gut microbiota in humans and 
has also been associated with opportunistic infections (13). However, 
Lachnospiraceae D4 did not produce disease in our monocolonized mice.  
Germ-free mice have proven to be a useful tool for studying host-microbe 
and microbe-microbe interactions within the GI tract (11). Germ-free mice have 
been used to examine how individual bacteria or bacterial communities influence 
colonization resistance against C. difficile (7, 21, 37, 44, 46). In many cases, the 
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bacteria employed in an attempt to interfere with C. difficile were previously 
described as “probiotic” organisms or undifferentiated groups of bacteria derived 
from healthy animals. In the current study, we examined bacteria that were 
previously observed to be associated with normal or diminished colonization 
resistance to C. difficile (30). In this way, we used the results of culture-
independent study of gut microbial ecology to inform and guide subsequent 
hypothesis-testing studies utilizing cultured bacterial isolates. We feel that this 
coupling of sequence-based microbial ecology studies with more traditional 
methods such as experimental animal infection represents a powerful way study 
bacterial pathogenesis.  
Multiple mechanisms have been proposed that explain how the 
indigenous microbiota can mediate colonization resistance (reviewed (4)). It is 
likely that several factors are involved in mediating colonization resistance, but 
the production of bacterial products that directly inhibit pathogens has received 
significant experimental attention. Several investigators have examined the ability 
of bacterial fermentation products including SCFAs to inhibit C. difficile growth. 
Some studies have shown that butyrate is capable of inhibiting C. difficile in vitro 
(26, 31) although contradicting reports exist (37). Lachnospiraceae organisms 
are notable in that many are capable of fermenting complex carbohydrates to 
SCFAs, which have an important role in maintaining intestinal homeostasis (1, 8, 
29, 48). We investigated whether SCFAs were associated with less C. difficile 
colonization in Lachnospiraceae pre-colonized mice and found that SCFA 
production did not correlate to lower C. difficile colonization levels (data not 
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shown). Therefore the decrease in C. difficile colonization levels due to 
Lachnospiraceae colonization is most likely attributed to the production of other 
metabolites or through other mechanisms.  
It has been proposed that rather than specific inhibition by the production 
of metabolites such as SCFA or antimicrobial compounds including bacteriocins, 
the indigenous microbiota could simply be competing for limiting nutrients, the 
so-called nutrient niche hypothesis. Stated in brief, this hypothesis maintains that 
an organism can outcompete another if it utilizes a limiting nutrient more 
efficiently. It is possible that the diminished levels of C. difficile in the presence of 
Lachnospiraceae is due to less effective utilization of specific nutrients by the 
former (16). It should be noted however, that our experiments don’t suggest that 
there is a simple mass effect with regards to nutrient utilization. When the levels 
of Lachnospiraceae D4 and E. coli colonization were measured, 
Lachnospiraceae D4 reached colonization levels 100-fold less than E. coli 
suggesting that simply occupying more “space” in gut, and presumably 
consuming proportionately more of the available resources does not necessarily 
contribute to colonization resistance.  
Corthier and colleagues demonstrated that a neonatal E. coli strain 
significantly inhibited C. difficile cytotoxin (7). In our studies an E. coli strain 
indigenous to wild-type mice had no such effect on C. difficile cytotoxin or 
colonization levels in germ-free mice. Naaber and colleagues examined the 
effect of over 50 Lactobacillus strains on C. difficile growth inhibition and found 
only five strains that had antagonistic activity toward C. difficile (27). These 
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studies suggest that although strains may belong to the same genus/species, 
variation in their individual genetic content results in functional differences. 
Similarly, it would be important to test the ability of other Lachnospiraceae 
isolates for their ability to inhibit C. difficile in vivo. It is possible that this is an 
ability that is shared by the Lachnospiraceae as a group or is associated with a 
function that is more restricted to certain members. 
 We have demonstrated that a single Lachnospiraceae organism (D4) was 
able to decrease the level of C. difficile colonization in vivo and improve clinical 
outcome. Therefore, we wanted to test the hypothesis that colonizing mice with a 
community of Lachnospiraceae organisms could further restore colonization 
resistance against C. difficile. Germ-free mice were inoculated with a 
combination of the remaining 13 slow growing Lachnospiraceae isolates and 
monitored for colonization. However, these isolates were unable to colonize the 
germ-free mouse gut. There are a number of reasons why this may have 
occurred. After examining the growth of each of these Lachnospiraceae isolates 
on enrichment agar, the average time for visible growth was between 3 and 4 
days. Additionally, growth in liquid culture was much less efficient. This slow 
growth may have hindered colonization since an organism must proliferate at an 
adequate rate if it is to maintain colonization. Additionally, many bacteria respond 
to co-colonization in species and sequence dependent manners. For example, in 
infants it has been shown that facultative anaerobes colonize the GI tract first, 
followed by obligate anaerobic organisms (34). A study performed by Syed and 
colleagues found that some strictly anaerobic bacteria could only colonize germ-
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free mice after mice were pre-colonized with E. coli (38). These studies all 
suggest that our 13 Lachnospiraceae isolates possible relied on other bacterial 
sources to provide metabolites or a gut environment conducive for colonization 
and proliferation in germ-free mice.  
Although monocolonization with Lachnospiraceae isolate D4 only partially 
restored C. difficile colonization resistance, there was complete restoration 
following the transfer of cecal contents from a wild-type mouse to germ-free 
mice. This implies that there are likely additive effects of specific microbiota in 
determining colonization resistance. Each member of the microbiota may partially 
contribute, but the entire community (or a specific subset) is required for 
complete colonization resistance. Others have observed only partial restoration 
of colonization resistance against C. difficile (7, 21). For instance, Itoh and 
colleagues colonized germ-free mice with multiple strains of Bacteroides and 
Lactobacilli and observed little antagonism toward C. difficile. Only when feces 
containing clostridia were administered to mice was C. difficile eliminated (21).  
In summary, our results show that a single component of the gut 
microbiota, a murine Lachnospiraceae isolate, was able to partially restore 
colonization resistance against C. difficile and improve clinical CDI outcome. 
Further investigation of the members within the Lachnospiraceae family 
potentially in combination with other taxonomically distinct members of the 
indigenous microbiota could lead to a greater understanding of mechanisms of C. 
difficile suppression and the role that these organisms play in protection against 
a variety of other pathogens and disease states. 
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The work described in this thesis examine the role of the microbiota in 
colonization resistance against C. difficile. The major findings are: 1) antibiotic 
administration resulted in shifts in the GI microbiota and these shifts were 
associated with the loss of colonization resistance to C. difficile; 2) specific 
microbial communities were associated with conferring resistance or susceptibility 
to C. difficile colonization; 3) a single component of the indigenous gut microbiota, 
a murine Lachnospiraceae isolate, was able to confer partial colonization 
resistance against C. difficile. The findings presented in previous chapters lay the 
foundation for many other studies that will further our knowledge on the role of the 
GI microbiota in preventing C. difficile colonization and pathogenesis. Future 
investigations developed from these studies will contribute to the field by 
attempting to unravel the mechanism(s) by which the indigenous GI microbiota 
contribute to colonization resistance against C. difficile and possibly other 
pathogens, thereby forging novel avenues towards treatment or prevention. This 
chapter aims to discuss the important findings in this thesis and elucidate possible 
mechanisms by which a specific subset of microbes, the Lachnospiraceae, 
contributes to colonization resistance against C. difficile. 
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4.2 Mechanisms by which Lachnospiraceae D4 contributed to partial 
restoration of colonization resistance against C. difficile in germ-free mice. 
In the past, many theories have been put forward on the various 
mechanisms by which the GI microbiota suppress invading pathogens. Several 
investigators have shown that the indigenous GI microbiota present a natural 
barrier that interferes with the establishment of pathogens (1, 21). Common 
mechanisms that have been proposed include: competitive exclusion which 
includes occupation of attachment sites (2, 62), consumption of nutrient sources 
(13, 22, 68), changes in oxidation-reduction potential and pH (21), and 
production of antimicrobial substances such as bacteriocins, SCFAs and 
hydrogen sulphide (13, 21, 50). Additionally, the gut microbiota may also 
stimulate the host to produce various antimicrobial compounds such as defensins 
(55). We will discuss which of these potential mechanisms Lachnospiraceae D4 
possibly utilized to contribute to partial restoration of colonization resistance 
against C. difficile in germ-free mice. 
4.2.1 Competitive exclusion 
A proposed mechanism by which the indigenous gut microbiota inhibit 
pathogen colonization is competition for specific physical niches within the 
intestine. These include either competition for attachment sites or physical space 
thereby competitively excluding the pathogen from the gut (12, 14, 23, 46, 66). 
Many researchers assume that adhesion of pathogenic bacteria to mucosal 
surfaces is the initial step of colonization and speculate that adhesion can be 
inhibited by physically blocking attachment receptors or by providing some form 
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of steric hindrance against the pathogen. Therefore, indigenous bacteria capable 
of attaching to the mucosal surface could prevent attachment and colonization by 
invading pathogens, a mechanism termed competitive exclusion (31).  
Many studies have examined the ability of C. difficile to attach to intestinal 
epithelial cells and mucus and concluded that C. difficile could attach to epithelial 
cells. However, these studies were conducted in vitro (59, 62, 63) which may not 
reflect the in vivo state. Borriello and colleagues attempted to elucidate the GI 
mucosal association of C. difficile in hamsters and concluded that C. difficile was 
able to adhere to mucosal sites of the GI tract (2). However, there is one caveat 
pertaining to how this experiment was conducted. The adherence of C. difficile 
was measured by removing luminal contents from mice and then C. difficile was 
cultured by plating gut tissue (2). This is not an ideal method to conclusively 
determine if, and more importantly, where C. difficile attaches in the gut. Direct 
visualization of C. difficile attachment to the gut epithelium using microscopic 
techniques such as scanning or electron microscopy would be conclusive. 
Therefore, it is still remains unclear whether C. difficile attaches directly to the gut 
epithelium or where it colonizes in mice (4).  
The epithelial layer of the colonic mucosa produces mucus, antimicrobial 
peptides and other proteins capable of forming electrostatic interactions with the 
lumen of the intestines (24, 37). Lachnospiraceae organisms have been shown 
to be closely associated with mucus on the colonic epithelial mucosa in both 
humans and conventional mice (11, 36, 37). However, there is a fundamental 
difference in the thickness of the mucus layers associated with conventional mice 
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compared to germ-free mice. Petersson and colleagues have shown that in 
germ-free mice the thickness of the mucus layer associated with the colonic 
epithelial mucosa is approximately four times thinner than that of conventional 
mice (45). These observations suggest that the germ-free state might not be 
ideal for examining specifically where certain bacteria might be localizing. 
However, for our purposes, I thought that determining the in vivo localization of 
C. difficile, E. coli and Lachnospiraceae D4 would provide some insight as to how 
these organisms were interacting in germ-free mice. Therefore, I examined 
colonic sections from germ-free mice pre-colonized with either Lachnospiraceae 
D4 or E. coli and infected with C. difficile VPI 10463 using fluorescent in situ 
hybridization (FISH) analysis. Results from this experiment indicated that C. 
difficile, E. coli and Lachnospiraceae D4 were primarily localized to the lumen of 
the colon. No attachment to the intestinal epithelium was observed by any of the 
organisms. However, comparatively fewer C. difficile were present in the lumen 
of mice pre-colonized with Lachnospiraceae D4 as compared with C. difficile or 
E. coli pre-colonized mice. This provided further confirmation of the decrease in 
C. difficile colonization observed in Lachnospiraceae D4 pre-colonized mice 
(Chapter 3, Figure 3.9). However, it was difficult to determine whether E. coli and 
Lachnospiraceae D4 had attached to mucus that was associated with the 
epithelial mucosa because of: (i) the presence of a loose and thin mucus layer 
that has been documented in germ-free mice (45); (ii) the fact that a fluorescently 
labeled probe specific for mucus identification was not used; and (iii) the FISH 
technique only provided visual data and could not provide direct evidence of 
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specific bacterial interaction. Therefore the fact that (i) E. coli and 
Lachnospiraceae D4 were present visually in comparatively similar numbers 
using FISH analysis and, (ii) E. coli colonized mice more than 100 times higher 
than Lachnospiraceae D4, suggests that physical competition for space was not 
associated with the decrease in C. difficile colonization by Lachnospiraceae D4.  
4.2.2 Changes in the chemical environment of the gastrointestinal tract 
One mechanism by which the GI microbiota could affect a pathogen is by 
changing the overall chemical environment of the gut. Changes in the community 
structure of the GI microbiota can dramatically alter the concentrations of various 
microbial metabolites (70). Many Lachnospiraceae organisms are capable of 
fermenting complex carbohydrates to SCFAs (7, 10). SCFAs, specifically 
acetate, propionate and butyrate are an important energy source for colonic 
enterocytes and provide other beneficial effects to the host. These include 
decreasing oxidative stress, inhibiting inflammation and even preventing 
carcinogenesis (20, 54, 60). Many studies have examined the ability of SCFAs to 
inhibit C. difficile growth. Rolfe and colleagues have shown that butyrate is 
capable of inhibiting C. difficile growth and causes loss of viability in vitro (50). In 
contrast, Su and colleagues repeated many of Rolfe’s experiments and found 
contradictory results. Su and colleagues did not observe any C. difficile growth 
inhibition when acetic, propionic or butyric acids were tested at physiological 
concentrations in vitro (57). To further confirm this result, these researchers 
administered a SCFA solution to C. difficile mono-associated germ-free mice by 
daily oral gavage but found no change in the levels of C. difficile colonization 
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since SCFAs did not accumulate in the GI tract (57). Finally to assume a more 
natural state of SCFA production, germ-free mice were di-associated with 
Clostridium butyricum, (an organism capable of producing high levels of butyrate 
in vivo) and C. difficile but the level of C. difficile colonization remained 
unchanged compared to mono-associated C. difficile controls (57).  
Other studies have shown that the concentration of SCFAs in mice and 
hamsters with an intact indigenous GI microbiota are high. These animals are 
only susceptible to C. difficile colonization following antibiotic treatment (50, 51, 
61). Therefore, it is possible that SCFAs could be a contributing factor to 
colonization resistance against C. difficile (50, 51, 61). The cecal microbial 
communities of our conventional C57BL/6 mice are predominated by 
Lachnospiraceae (49). Previous studies conducted in our lab demonstrate the 
presence of high levels of SCFAs in wild-type mice (data not shown). We have 
also shown that following antibiotic treatment, the levels of Lachnospiraceae are 
decreased (Chapter 2, Figure 2.7). Additionally, measurement of SCFAs 
following antibiotic treatment are reduced dramatically when compared to control 
animals. This led us to hypothesize that the decrease in C. difficile colonization 
levels observed by pre-colonization of germ-free mice with Lachnospiraceae D4 
might be associated with the production of SCFAs. Therefore, the level of SCFAs 
produced by Lachnospiraceae D4 was measured in vitro in rich broth (brain heart 
infusion) by gas chromatography mass spectrometry (GC-MS). Both 
Lachnospiraceae D4 and E. coli produced only acetate. However, 
Lachnospiraceae D4 produced 40% more acetate than E. coli (data not shown). 
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Furthermore, we also measured the concentration of SCFAs present in the cecal 
contents of germ-free mice mono-associated with either E. coli or 
Lachnospiraceae D4 and found no difference in the SCFA concentration as 
compared to germ-free mice controls. This result suggested that SCFA 
production by Lachnospiraceae D4 was not associated with the decrease in C. 
difficile colonization levels observed in germ-free mice. The decrease in C. 
difficile colonization levels by the Lachnospiraceae D4 could be due to the 
production of other metabolites that changed the chemical environment of the gut 
making it unfavorable for efficient C. difficile colonization. On the other hand, the 
Lachnospiraceae family is very diverse and consists of numerous genera that are 
associated with the production of high concentrations of SCFAs. Hence, the fact 
that SCFAs were not associated with lowered C. difficile colonization in our germ-
free studies does not rule out the fact that these substances may play a role in 
contributing to colonization resistance against C. difficile in wild-type mice with a 
fully intact microbiota.  
4.2.3 Production of antimicrobial substances 
Another possible mechanism by which the indigenous GI microbiota 
directly inhibits growth and proliferation of pathogenic bacteria is through the 
production of antimicrobial substances (8). This antimicrobial activity can be 
multi-factoral. It can include the production of bacteriocins, SCFAs (as discussed 
earlier) which lower gut pH, nitric oxide, hydrogen sulphide, and hydrogen 
peroxide (27, 35, 43, 48). It is estimated that many bacterial species in the gut 
can produce antimicrobial substances. For instance, Lactococcus lactis has been 
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shown to secrete a cationic peptide that has antimicrobial activity against several 
C. difficile strains in vitro (48). Additionally, O’Shea and colleagues performed a 
culture-based screening of over 40,000 lactic acid bacterial colonies to assess 
antimicrobial activity from a variety of intestinal sources. These researchers 
demonstrated that only 23 strains were capable of producing a bacteriocin-like 
substance (40). The Lachnospiraceae family consists of many genera that have 
not been widely studied. Hence little information is available on their ability to 
produce bacteriocins or inhibitory compounds. One Lachnospiraceae member 
that has been well studied, Butyrivibrio fibrisolvens, has been shown to produce 
compounds (Butyrivibriocins) that inhibit the growth of a number of different 
bacterial species (7, 25). However the ability of Lachnospiraceae to inhibit C. 
difficile growth through the production of bacteriocins have not been 
demonstrated. 
 In this thesis I initially performed a simple in vitro test to determine 
whether Lachnospiraceae D4 was capable of producing and secreting an 
antimicrobial substance against C. difficile. In this experiment, C. difficile was 
streaked onto BHIS plates and then cross-streaked with Lachnospiraceae D4. 
Here, we would predict that if Lachnospiraceae D4 produced a bacteriocin or 
antimicrobial substance that inhibited C. difficile growth it would be secreted into 
the media surrounding the area of Lachnospiraceae D4 growth. Ideally this would 
result in a clear zone which would indicate that C. difficile growth was inhibited. 
However, no C. difficile inhibition was observed using this technique. In another 
in vitro experiment, Lachnospiraceae D4 and C. difficile were co-cultured in BHIS 
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broth and a growth curve of both organisms was performed over a 12-hr period 
followed by selective plating at 3-hour intervals. The expectation for this 
experiment was if Lachnospiraceae D4 produced an inhibitory substance, little to 
no C. difficile growth would be observed. Our results revealed that C. difficile 
growth was not significantly decreased compared to a C. difficile only control. 
These data do not provide evidence that production of bacteriocins or 
antimicrobial compounds by Lachnospiraceae D4 was responsible for the relative 
decrease of C. difficile colonization in germ-free mice.  
4.2.4 Competition for Nutrients 
It is also theorized that the indigenous GI microbiota utilize an appreciable 
portion of available nutrients or substrates in the gut thereby preventing the 
availability of nutrient reservoirs to invading pathogens (13, 15, 19). Disruption of 
the normal indigenous microbiota allows this nutrient reservoir to become 
available. This was demonstrated by Guiot and colleagues where E. coli growth 
was suppressed when directly injected into the cecum of a live rat but upon 
antibiotic administration, the E. coli population grew efficiently (19). Previous 
studies have investigated nutrient competition in the suppression of C. difficile 
using an in vitro model of continuous-flow (CF) culture, which closely reproduces 
the GI ecosystem found in a mouse cecum (16, 67, 68). Wilson and colleagues 
have investigated the role of nutrient competition by the colonic microbiota in C. 
difficile suppression (69). These researchers observed that C. difficile proliferated 
efficiently in CF culture in the presence of carbohydrate sources such as glucose, 
N-acetylglucosamine and N-acetylneuraminic acid but not when galactose, 
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mannose, xylose, arabinose and fucose was added. These results suggested 
that the latter carbohydrates were not C. difficile’s primary substrate source (69). 
It has been demonstrated that bacteria from murine luminal contents inoculated 
into CF culture media consume between 75-99.5% of the total carbohydrates 
present. On the other hand, amino acids are not extensively used for metabolism 
by C. difficile or other cecal bacteria in CF culture (68).  
The nutrient–niche hypothesis was initially presented by Freter and 
colleagues. In general, this concept states that species can coexist in the gut 
because each organism is capable of growing faster than all others on one or a 
few limiting nutrients. The rate of growth of each organism during colonization 
must be at least equal to it wash out rate from the gut (12, 14(29). In other words, 
two strains cannot grow equivalently in the gut as the metabolically efficient strain 
will out compete the other for similar nutrients unless the less efficient organism 
attaches to the gut wall or mucus layer associated with the gut epithelium. Based 
on my results I could not confirm that Lachnospiraceae D4 or C. difficile adheres 
to the mucus associated with the gut wall in germ-free mice. Therefore a possible 
mechanism by which Lachnospiraceae D4 contributed to colonization resistance 
against C. difficile was through direct competition for similar nutrients or 
substrates (not utilized by E. coli) within the gut. Later in this chapter I will 
discuss experiments that could be used to provide insight on whether 
Lachnospiraceae D4 and C. difficile competed for similar nutrient sources.  
 
                                     152 
4.2.5 Immuno-modulatory effects 
There are indirect mechanisms by which the indigenous gut microbiota 
inhibit enteric pathogen growth (4). Gut bacteria modulate the innate and 
adaptive immune systems by stimulating toll like receptors (TLRs) and by up-
regulating cytokine expression in dendritic cells and peripheral white blood cells 
(18, 47). One way this is done is through the stimulation of host antimicrobial 
defense pathways, for example, the production of antimicrobial peptides such as 
RegIIIγ and defensins.  
Changes in the gut microbial community can indirectly affect colonization 
resistance. For example, decreasing the overall bacterial community through the 
administration of antibiotics can result in decreased host production of the 
antimicrobial peptide RegIIIγ (6). RegIIIγ is one of several antimicrobial peptides 
produced by Paneth cells that specifically target Gram-positive bacteria because 
it binds to their surface peptidoglycan layer. The alteration of host immunity can 
lead to colonization with vancomycin-resistant Enterococcus (VRE) (3). In the 
murine model of CDI, the use of the five antibiotic cocktail resulted in marked 
decreases in the expression of RegIIIγ. However, unlike the case with VRE, this 
decrease in antimicrobial peptide expression was not associated with decreased 
colonization resistance to C. difficile. In fact, administration of clindamycin alone 
resulted in a temporary decrease in colonization resistance without any changes 
in RegIIIγ expression. These results suggested that RegIIIγ was not associated 
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with inhibiting C. difficile colonization. Since RegIIIγ targets Gram-positive 
bacteria it is highly unlikely that Lachnospiraceae D4 would stimulate its release.  
 Defensins are a family of proteins that can be secreted by immune cells 
such as neutrophils, intestinal Paneth cells and epithelial cells, which have 
bactericidal properties against enteric pathogens (32, 52). Gut bacteria may 
stimulate defensin activity by stimulating defensin expression, thereby 
strengthening intestinal defenses (4, 34). Additionally, many defensins are 
synthesized in an inactive form and must be activated by matrilysin (proteolyic) 
cleavage (52). One study has shown that mice defective in matrilysin production 
were more susceptible to severe Salmonella infection. This study also 
demonstrated that germ-free mice do not produce matrilysin which suggests that 
bacteria must be present in mice to stimulate matrilysin production in the 
intestine (30). Therefore, an alternative way in which gut bacteria could stimulate 
defensin activity is by stimulating the production of matrilysin, resulting in 
increased levels of activated defensins in the GI tract. Currently, defensin 
production has not been implicated as a mechanism of colonization resistance 
against C. difficile in vitro or in vivo. Germ-free mice colonized with 
Lachnospiraceae D4 prior to C. difficile exhibited a decrease in the level of C. 
difficile colonization. It is not known whether Lachnospiraceae organisms are 
capable of stimulating defensin expression in the host or are capable of 
producing matrilysin that could cleave and activate defensin molecules. 
Therefore, I will propose experiments to examine whether the production of 
                                     154 
defensins stimulated by Lachnospiraceae D4 colonization, contributed to the 
suppression of C. difficile in germ-free mice.  
Bifidobacterium and Lactobacillus have been shown to stimulate the host 
innate immune response and lamina propria dendritic cells by providing an anti-
inflammatory effect (9, 38, 41). The host immune response has an important 
influence on C. difficile colonization and disease severity. For instance, it has 
been demonstrated that increased titers of antibodies to toxin A were associated 
with a decrease in CDI severity and C. difficile asymptomatic carriage (26, 28). 
Clinical evidence has linked a reduction in the level of colonization of members of 
the Lachnospiraceae family to chronic inflammatory disorders such as 
inflammatory bowel disease (56, 65). However, many of these studies have 
theorized that the inflammatory effect was due to differences in host immune 
response and metabolite production in the gut. For instance, Lachnospiraceae 
are capable of fermenting complex carbohydrates to SCFAs (7, 10). Specifically, 
butyrate is essential for maintaining intestinal homeostasis and has anti-
inflammatory properties (20). However, due to limited knowledge and availability 
of cultivated members from the Lachnospiraceae family, work on the regulation 
of the host immune response in relation to C. difficile colonization have not been 
previously performed.   
Many of the experiments performed in this thesis include the use of germ-
free animals. Germ-free mice contain abnormal numbers of several immune cell 
types and cell products and possess deficiencies in local and systemic lymphoid 
structures. As a result, there may be reduced levels of secreted immunoglobulins 
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(IgA, IgG) and irregular cytokine levels/profiles (32, 39). However, bacterial 
colonization reverses this observed phenotype (33). Therefore, further 
examination of the level of pro-inflammatory (IL-1, IL-6, TNF alpha) or anti-
inflammatory (IL10, IL-12) cytokines produced in germ-free mice pre-colonized 
with Lachnospiraceae D4 prior to and after C. difficile challenge could provide a 
more complete analysis on the engagement of the murine immune system in 
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4.3 Summary model by which Lachnospiraceae D4 partially suppressed C. 
difficile colonization in germ-free mice 
 
 
Figure 4.1  Model summarizing potential mechanisms by which Lachnospiraceae 
D4 partially restored colonization resistance against C. difficile. The gut 
microbiota could inhibit C. difficile colonization by direct competition for similar 
nutrients, production of SCFAs, competition for physical space and production of 
microbial products such as bacteriocins. It can also stimulate the immune system 
indirectly which can influence the adaptive immune response resulting in the 
production of antibodies, or it can stimulate an innate immune response causing 
the release of antimicrobial peptides. However, for Lachnospiraceae D4, some of 
these potential mechanisms can be eliminated as designated by the orange 
colored X. Stimulation of the adaptive immune response, physical competition for 
space and SCFA production can be eliminated. Figure adapted from (5) 
 
Many mechanisms have been implicated in the suppression of C. difficile 
colonization by the indigenous gut microbiota. These include competition for 
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stimulation of the adaptive and innate immune response (5). I have demonstrated 
that Lachnospiraceae D4 partially restores colonization resistance against C. 
difficile. Although the exact mechanism by which this occurred is undefined, my 
data suggest that SCFA production by Lachnospiraceae D4 was not associated 
with the decrease in C. difficile colonization and toxin production in germ-free 
mice. Additionally, competition for physical space was also not associated for the 
decrease in C. difficile colonization levels. My results demonstrated that even 
though the level of colonization by Lachnospiraceae D4 was approximately 100 
times lower than E. coli, E. coli was not associated with colonization resistance 
against C. difficile. Finally, stimulation of the adaptive immune response can be 
eliminated as a potential mechanism by which Lachnospiraceae D4 suppressed 
C. difficile colonization. The adaptive immune response takes weeks to produce 
antibodies against pathogens. In Lachnospiraceae D4 colonized mice challenged 
with C. difficile VPI 10463, CDI was acute. As a result, this time period was not a 
long enough for the development of antibodies against C. difficile. 
Therefore, I am postulating two mechanisms by which Lachnospiraceae 
D4 potentially contributed to colonization resistance against C. difficile. These 
are: (i) both Lachnospiraceae D4 and C. difficile, but not E. coli, competed for 
similar nutrient resources. As a result of this competition, Lachnospiraceae D4 
was able to keep the C. difficile population under control; (ii) Lachnospiraceae D4 
had a positive effect on the host immune response by inducing increased 
production of defensins (or matrilysin which activate defensins) that targeted C. 
difficile. Because of the reduction in the level of C. difficile colonization, there was 
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a corresponding decrease in toxin production. In turn, this resulted in only 
moderate disease and improved histopathology in germ-free mice pre-colonized 
with Lachnospiraceae D4 and infected with C. difficile.  
4.4  Future directions 
The goals of the research presented in this thesis were two-fold. First, I 
wanted to determine the effect of antibiotic administration in conferring 
susceptibility or resistance to C. difficile infection in murine models. Our findings 
suggested that specific microbial communities, the Lachnospiraceae family, may 
play a role in conferring resistance to C. difficile colonization and disease 
severity. Lastly, I wanted to determine whether a single component of the 
indigenous gut microbiota, a Lachnospiraceae isolate, was involved in mediating 
colonization resistance against C. difficile. My findings demonstrated that a single 
Lachnospiraceae isolate (D4) restored partial colonization resistance against C. 
difficile. However, the mechanism by which Lachnospiraceae D4 contributed to 
colonization resistance against C. difficile is undefined. To test the model 
described previously, I would propose the following specific aims and 
experiments to unravel the mechanism by which Lachnospiraceae D4 mediated 
colonization resistance against C. difficile.  
4.4.1 Aim 1: To investigate whether partial suppression of C. difficile 
colonization in Lachnospiraceae D4 pre-colonized germ-free mice is 
associated with defensin production  
Rationale  
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Defensins are a family of proteins that are secreted by immune cells and 
have bactericidal properties against enteric pathogens (32, 52). GI bacteria may 
stimulate defensin activity by stimulating the synthesis of defensin expression or 
proteases such as matrilysin that activate defensins (4, 34). Matrilysin, a matrix 
metalloproteinase (MMP7), is predominantly expressed by mucosal epithelial 
cells in normal tissues and in the ileal tissue in mice. A study performed by 
Lopez-Boudo and colleagues suggest that bacterial exposure is a potent and 
physiologically relevant signal capable of regulating matrilysin expression in 
epithelial cells (30). The only previous report exploring whether defensins protect 
against C. difficile was performed in vitro using a human epithelial cell line. These 
investigators reported that human alpha defensins inhibited C. difficile TcdB in 
vitro (17). However, the effects of these molecules have not been previously 
reported in vivo. I also reported RegIIIγ, another antimicrobial peptide produced 
by the host in response to certain bacteria, was measured in mice presenting 
with mild and severe CDI. Mice with severe CDI had a six-fold increase in the 
level of RegIIIγ when compared to mice with mild CDI. This result suggested that 
a direct relationship between changes in RegIIIγ expression and colonization 
resistance against C. difficile could not be made. However, the fact that RegIIIγ 
was not associated in preventing C. difficile colonization does not necessarily 
suggest that other antimicrobial peptides such as defensins function in the same 
way. In mice, there is evidence for the expression of 19 or more (highly similar) 
defensin genes in the small intestine (42).  In order to determine whether 
Lachnospiraceae D4 stimulated host defensin expression, I will measure the 
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level of Paneth cell defensin effector expression in intestinal tissue of germ-free 
mice monocolonized with Lachnospiraceae D4 and di-associated with C. difficile.  
Experimental approach  
Comparison of Paneth cell defensin effector expression will be measured 
in mice monocolonized with Lachnospiraceae D4, E. coli and C. difficile. Germ-
free mice monocolonized with C. difficile and E. coli will function as controls to 
determine whether the defensin levels are increased or decreased when 
compared to Lachnospiraceae D4 monocolonized mice. Additionally, germ-free 
mice will also be di-associated with Lachnospiraceae D4 or E. coli and C. difficile 
similar to that described in Chapter 3, section 3.2.5. Specifically, RNA will be 
isolated and quantified from ileal tissue as described by Wehkamp (64) then 
reverse transcribed to cDNA. Gene specific real time PCR using cDNA as a 
template will be done with specific oligonucleotide primer pairs for the following 
murine alpha defensin effectors: cryptidin 1, cryptidin 2, cryptidin 4, cryptidin 5, 
as previously described by Salzman and colleagues (52). Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) will be used as a housekeeping control 
gene for data normalization.   
Expected results and alternative approaches 
I expect that there will be differential expression of specific defensins 
across all experimental groups of mice. Ideally, I expect that defensins present or 
up regulated in response to both E. coli and C. difficile colonization will not be 
associated with contributing to C. difficile colonization resistance. On the other 
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hand, defensins up regulated in response to Lachnospiraceae D4 and C. difficile 
co-colonization, but not in response to E. coli and C. difficile co-colonization may 
be important for inhibiting C. difficile growth. One potential pitfall to this approach 
is that there are approximately 19 different murine cryptidins currently identified 
(42). Therefore, additional oligonucleotide primer pairs for the remaining murine 
cryptidins will need to be designed based on sequences provided by Ouellette 
and colleagues (42). However, examining which cryptidins are up or down 
regulated across the various experimental groups of mice may be challenging. 
Therefore, an alternate approach that can be used to examine whether defensins 
play a role in C. difficile inhibition is to first examine which murine cryptidin 
inhibits C. difficile growth. An in vitro based bactericidal assay can be performed 
by growing C. difficile to log phase and inoculating 5 ml aliquots of C. difficile 
culture with purified murine cryptidin. At 30-minute intervals, I could sample each 
C. difficile aliquot over a 2-hour period and perform dilution plating on TCCFA to 
measure the level of C. difficile inhibition. This experiment will provide information 
on specific cryptidins that may be important for inhibiting C. difficile growth. As a 
result, this would be a targeted approach to measure the levels of specific 
cryptidins across the groups of germ-free mice.  
One possible experimental outcome is that no change in defensin level will 
be observed across all experimental groups of mice used. In this case I will 
measure the levels of matrilysin (MMP7) in all experimental groups of mice. 
MMP7 can be measured in serum using a fluorescent based immunoassay 
method as described in Sarkissian et. al. (53). This will determine whether 
                                     162 
Lachnospiraceae D4 promoted the activation of defensins, which in turn partially 
suppressed C. difficile colonization. If no association can be made from these 
experiments then I will rule out the possibility that defensins contributed to the 
decrease in C. difficile colonization in Lachnospiraceae D4 pre-colonized mice. 
4.4.2  Aim 2: To determine whether competition for similar nutrients by 
Lachnospiraceae D4 and C. difficile is associated with decreased C. difficile 
colonization  
Rationale 
Many Lachnospiraceae members are capable of fermenting a plethora of 
soluble carbohydrate sources such as glucose, maltose, sucrose, fructose, 
cellobiose, xylose and arabinose (7, 10). Many of these organisms can also 
utilize amino acids and complex nitrogen sources such as casein, peptone and 
trypticase (7). Currently, I have not directly tested the carbon sources that 
Lachnospiraceae D4 utilizes. Both Lachnospiraceae D4 and C. difficile can grow 
on various types of culture media such as modified peptone yeast glucose 
(MPYG), BHIS and TCCFA (after 72 hours incubation at 37°C). Based on these 
data, I hypothesize that both of these organisms can utilize fructose, glucose and 
dextrose as carbohydrate sources and various nitrogen sources. Additionally, E. 
coli can grow on MPYG, BHIS and other enrichment media suggesting it too can 
utilize similar substrate sources. Thus, understanding the specific amino acids, 
carbohydrates or other carbon sources utilized by both Lachnospiraceae D4 and 
C. difficile, but not E. coli may provide a mechanism as to the exact mode by 
which Lachnospiraceae D4 partially suppressed C. difficile colonization.  
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Experimental approach 
In order to determine substrate sources that are utilized by both 
Lachnospiraceae D4 and C. difficile but not E. coli, an in vitro approach can be 
utilized. Here I will grow C. difficile, E. coli and Lachnospiraceae D4 separately, 
and in co-culture (Lachnospiraceae D4 and C. difficile; E. coli and C. difficile) in 
complex media consisting of many different carbon, nitrogen and amino acid 
sources. Cultures that consist of individual bacteria will be grown to mid-log 
phase as determined by optical density (OD) measurement. Samples will be 
collected and centrifuged to obtain cell free supernatants. Co-cultures will be 
inoculated with 1x103 CFU of each organism and then grown for 12 hours after 
which samples will be collected and centrifuged to obtain cell free supernatants. 
To measure the concentrations of carbohydrates present in each sample, a 
method described by Perini and colleague using fluoro-metric analysis of acid 
hydrolyzed samples and liquid chromatography will be done (44). Amino acid 
analysis will be performed using mass spectrometry (58). These data will provide 
the concentrations of each substrate utilized by each organism as compared to 
fresh media. Comparative analysis can be used to determine substrates that are 
utilized by both C. difficile and Lachnospiraceae D4 but not E. coli.  
Expected results and alternate approaches  
Examining the growth of each organism in complex media will provide 
information on the types of nutrients utilized. I expect that Lachnospiraceae D4, 
E. coli and C. difficile when grown in monoculture, will utilize many carbohydrates 
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and amino acids. This data will be important to compare the levels of 
carbohydrates and amino acids that are utilized when the organisms are grown in 
co-culture. For example, if both C. difficile and Lachnospiraceae D4 but not E. 
coli utilized mannose in mono-culture, then Lachnospiraceae D4 and C. difficile 
will be competing for the same sugar when grown in co-culture. In this case, I will 
expect that the level of mannose will be completely exhausted in the supernatant. 
On the other hand, I would expect that the level of mannose measured when E. 
coli and C. difficile are grown in co-culture to be higher. One caveat to this 
experiment is that the generation time for E. coli is faster than C. difficile. As a 
result of the static nature of the culture, C. difficile may be out competed by E. 
coli since it will utilize other resources in the media which may adversely affect C. 
difficile growth.  
Although in vitro approaches can be useful, it does not represent what 
occurs in vivo. An alternate approach to test nutrient competition is to use germ-
free mice. Germ-free mice will be mono-colonized with E. coli, Lachnospiraceae 
D4, C. difficile (630 strain) or di-associated with either E. coli or Lachnospiraceae 
D4 and C. difficile. Luminal contents will be collected along with contents from 
untreated germ-free mice as controls. Similar methods for carbohydrate (44) and 
amino acid analysis (58) will be used to measure the concentrations of various 
substrates differentially present in the luminal contents of each mouse from each 
group. Extrapolation of these data will allow us to determine whether competition 
for similar nutrients contributed to the decrease in C. difficile colonization in 
Lachnospiraceae D4 pre-colonized mice.  
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Summary and significance 
Investigating potential mechanism(s) by which Lachnospiraceae D4 
partially suppressed C. difficile colonization in germ-free mice could lead to the 
identification of general mechanism(s) used by other Lachnospiraceae organisms 
to mediate colonization resistance against C. difficile.  
 
4.5 Overall summary and conclusions 
A number of important conclusions can be made based on work presented 
in this thesis. I have demonstrated that antibiotic-treated mice can be utilized to 
study the effect of altering the indigenous gut microbiota as it relates to loss of 
colonization resistance against C. difficile. I have demonstrated that both the five-
antibiotic cocktail and clindamycin were required to overcome colonization 
resistance to C. difficile. A key feature of this model was the ability to modulate 
disease severity by altering the challenge dose of C. difficile. When mice were 
challenged with 105 C. difficile VPI 10463 organisms, approximately 60% were 
moribund with high C. difficile load and cytotoxin levels. The remaining mice had 
less severe disease with significantly less C. difficile load and cytotoxin. This 
clinical phenotype allowed us to investigate differences in microbial ecology 
following antibiotic treatment and C. difficile infection. Shifts in microbial ecology 
following antibiotic treatment were associated with susceptibility to C. difficile 
infection. For instance, the gut community of mice pre-treated with the five-
antibiotic cocktail and clindamycin shifted from a predominance of Firmicutes 
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(Lachnospiraceae) to Proteobacteria (E. coli). The gut communities of mice with 
severe CDI were similar to the gut community of antibiotic treated mice. On the 
other hand, the gut community of mice with clinically mild disease seemed to be 
recovering to the baseline community with a predominance of Lachnospiraceae.  
I have also demonstrated that treatment of mice with cefoperazone results 
in severe disruption of the gut microbiota. These mice were also highly 
susceptible to C. difficile colonization and severe disease regardless of C. difficile 
VPI 10463 challenge dose. After a six-week recovery period, mice were 
susceptible to CDI following a single dose of clindamycin which suggested that 
cefoperazone was associated with prolonged alteration of the gut community.  
These results suggest that clinical outcomes following antibiotic pre-treatment 
and C. difficile infection may depend on the level of recovery of the altered 
microbial community toward the baseline state. For instance, if the altered 
microbial community recovers slowly then C. difficile may proliferate and produce 
toxin readily. This in turn may overwhelm the host and result in severe CDI. 
However, if the altered community is able to reach a level of recovery that is 
faster than C. difficile proliferation, then the indigenous (still altered) microbial 
community may be able to control the level of C. difficile expansion.  
Based on the observed differences of GI communities in mice with mild 
and severe CDI, I tested the hypothesis that Lachnospiraceae was less 
permissive to C. difficile colonization than E. coli. Murine Lachnospiraceae and E. 
coli isolates were isolated from wild-type mice and tested in germ-free mice. This 
investigation revealed that Lachnospiraceae organisms play an important role in 
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limiting C. difficile colonization. Specifically, colonization of germ-free mice with a 
single Lachnospiraceae isolate D4 significantly decreased the level of C. difficile 
colonization and toxin by two different C. difficile strains and improved clinical 
CDI outcome when compared to E. coli pre-colonized and C. difficile control 
mice. Additionally, higher levels of bacterial colonization were not associated with 
decreased C. difficile colonization which suggests that C. difficile colonization 
was independent of bacterial load. I also investigated whether the production of 
SCFAs was a potential mechanism by which Lachnospiraceae D4 partially 
restored colonization resistance against C. difficile but found that it was not 
associated with the decrease in C. difficile colonization levels. Additionally, I also 
determined that competition for physical space was not associated with the 
partial suppression of C. difficile colonization. Although the specific 
mechanism(s) by which Lachnospiraceae D4 partially restored colonization 
resistance against C. difficile remains undefined, I postulate that nutrient 
competition and the production of immune-modulatory factors such as defensins 
may be involved.  
Overall, the findings in this thesis demonstrate that: (1) the microbial 
community structure of the indigenous gut microbiota plays an important role in 
colonization resistance against C. difficile and disease severity, (2) the use of 
various tractable murine models are useful in studying the indigenous gut 
microbiota and (3) Lachnospiraceae plays an important role in contributing to 
colonization resistance against C. difficile. These results lay the groundwork for 
future study of other Lachnospiraceae and members of the GI community and 
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their role in contributing to colonization resistance against C. difficile and other 
pathogens.
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